

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/705, A01K 67/027, C12N 5/10, C12Q 1/68, G01N 33/50		A1	(11) International Publication Number: WO 00/60069 (43) International Publication Date: 12 October 2000 (12.10.00)
(21) International Application Number: PCT/CA00/00354 (22) International Filing Date: 3 April 2000 (03.04.00) (30) Priority Data: 60/127,452 1 April 1999 (01.04.99) US 60/173,826 30 December 1999 (30.12.99) US (71) Applicant: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO [CA/CA]; 106, Simcoe Hall, 27 King's College Circle, Toronto, Ontario M5S 1A1 (CA). (72) Inventors: ST. GEORGE-HYSLOP, Peter, H.; 210 Richview Avenue, Toronto, Ontario M5P 3G3 (CA). FRASER, Paul, E.; 611 Windermere Avenue, Toronto, Ontario M6S 3L9 (CA). (74) Agent: RAE, Patricia, A.; Sim & McBurney, 6th floor, 330 University Avenue, Toronto, Ontario M5G 1R7 (CA).		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: A PRESENILIN ASSOCIATED MEMBRANE PROTEIN AND USES THEREOF			
(57) Abstract			
<p>Presenilin Associated Membrane Protein (PAMP), and nucleic acids encoding this protein, are provided, PAMP and PAMP nucleic acids provide diagnostic and therapeutic tools for evaluating and treating or preventing neurodegenerative diseases. In a specific embodiment, mutations in PAMP are diagnostic for Alzheimer's Disease or spina bifida. The invention further relates to screening, particularly using high-throughput screens and transgenic animal models, for compounds that modulate the activity of PAMP and presenilins. Such compounds, or gene therapy with PAMP, can be used in treating neurodegenerative diseases, particularly Alzheimer's Disease. In addition, the invention provides PAMP mutants, nucleic acids encoding for PAMP mutants, and transgenic animals expressing PAMP mutants, which in a preferred aspect result in biochemical changes similar to those induced by mutations in βAPP, PS1, or PS2 associated with familial Alzheimer's Disease.</p>		<p>Hum: 1 MATAGGGSGADPGSRGLRLLSFCVLLAGLCRGNVERKIYIPLNKTAPCVRLNATHQI 60 Mou MAT GSG DPGSRGL LLSF V+LAGLC GNSVERKIYIPLNKTAPCVRLNATHQI Dros: 1 A + +G K+Y P+ A C R LN THQ C.ele L +++AG+C G S + + + + C R N TH+</p> <p>Hum 61 GCQSSISGDTGVIHVVEKEEDLQWVLTGDPNPPYMWLLESKHFTRLDMEKLKGRTSRIAG 120 Mou GCQSSISGDTGVIHVVEKEEDL+VWLTGDPNPPYMWLLE K FTRD+MEKLK TSRIAG Dros GC S+ SG GV+H++ E DL+++L+ P+PPY ++ FTR+ + +LK + C.eleg GCQ++ +G+I ++K+ED + W + Y LL RD + +LK + ++G</p> <p>Hum: 121 LAVSLTKPSPASGFSFVQCPNDGFGVYSNSYGPEFAHCREIQWNSLGNLAYEDFSFPI 180 Mou LAV+L KP+ S FSPSVQCPNDGFG YSNSYGPEFAH ++ WN LG LAYED SFPI Dros + + + + + FS + CPN G+ S S + + + WN G GL +EDF FPI C.eleg + +S + ++ S +CPN Y E+ E + NS G+GL D+ +</p> <p>Hum: 181 FLEEDENETKVIKQCYQDHNLSQNGSAPTFLCAMQLFSHMHAVISTATCMRRSSIQTSTF 240 Mou FLEDE+ETKVIKQCYQDHNLS QNGSAP+FLCAMQLFSHMHAVISTATCMRRS IQSTF Dros: + + D ++ ++C+QD N + LCA+++ S M A ++T CMRR++ + C.eleg +++ + ++I+CY N + + +P C M A ++ C RR + F</p> <p>Hum: 241 SINPEIVCDPLSDYNVWSMLKPINTTGLKPDPRVVAATRLDSRSFF+WNVAPGAESAV 299 Mou SINPEIVCDPLSDYNVWSMLKPINT+ L+PD RVVVAATRLDSRSFF WNVAPG ESAV Dros ++ CDPL NV P +T T+ +++ ++ RLD+ + F V GA ++ C.eleg +N + +C + N+++ PI T+ T+ + + + R+DS ++ G S +</p> <p>Hum: 300 ASFVTQLAAAEALQKAPDVTTLPRNVFVFFQGETFDYIGSSRMVYDMEKGFPPVQLENV 359 Mou ASFVTQLAAAEAL KAPDVTTL.RNVFVFFQGETFDYIGSSRMVYDME GKFPV+LEN+ Dros F A LQ P + NV+FV F GE++DYIGS R VYDMEK +Fp+ ++ C.eleg S ++ LAAA ++/QKA + + RNV.F FF GE+ DYIGS Y ME GKFP+ +</p>	

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

A PRESENILIN ASSOCIATED MEMBRANE PROTEIN AND USES THEREOF

FIELD OF THE INVENTION

5 The present invention relates generally to the field of neurological and physiological dysfunctions associated with neuropsychiatric and developmental diseases, especially Alzheimer's Disease. More particularly, the invention is concerned with the identification of proteins associated with neuropsychiatric and developmental diseases, especially
10 Alzheimer's Disease, and relates to methods of diagnosing these diseases, and to methods of screening for candidate compounds which modulate the interaction of a certain protein, specifically Presenilin Associated Membrane Protein ("PAMP"), with presenilin proteins.

BACKGROUND OF THE INVENTION

15 Alzheimer's Disease (AD) is a degenerative disorder of the human central nervous system characterized by progressive memory impairment and cognitive and intellectual decline during mid to late adult life (Katzman, *N Eng J Med* 1986;314:964-973). The disease is accompanied by
20 a constellation of neuropathologic features principal amongst which are the presence of extracellular amyloid or senile plaques, and neurofibrillary tangles in neurons. The etiology of this disease is complex, although in some families it appears to be inherited as an autosomal dominant trait. Genetic studies have identified three genes associated with the development of AD, namely:
25 (1) β -amyloid precursor protein (β APP) (Chartier-Harlin *et al.*, *Nature* 1991;353:844-846; Goate *et al.*, *Nature* 1991;349:704-706; Murrell *et al.*, *Science* 1991;254:97-99; Karlinsky *et al.*, *Neurology* 1992;42:1445-1453; Mullan *et al.*, *Nature Genetics* 1992;1:345-347); (2) presenilin-1 (PS1) (Sherrington *et al.*, *Nature* 1995;375:754-760); and (3) presenilin-2 (PS2)
30 (Rogaev *et al.*, *Nature* 1995;376:775-778; Levy-Lehad *et al.*, *Science* 1995; 269:970-973).

 Abnormal processing of β APP with overproduction of amyloid- β is also a feature of other CNS diseases, including inherited and sporadic forms of amyloid angiopathy, which presents with intracerebral bleeding (Levy
35 *et al.*, *Science* 1990;248:1124-1126). Thus, abnormalities of presenilin proteins and PS-interacting proteins may affect these diseases as well.

The presenilin genes (PS1 - *PS1* and PS2 - *PS2*) encode homologous polytopic transmembrane proteins that are expressed at low levels in intracellular membranes including the nuclear envelope, the endoplasmic reticulum, the Golgi apparatus and some as yet uncharacterized intracytoplasmic vesicles in many different cell types including neuronal and non-neuronal cells (Sherrington *et al.*, *supra*; Rogaev *et al.*, *supra*; Levy-Lahad *et al.*, *supra*; Doan *et al.*, *Neuron* 1996;17:1023-1030; Walter *et al.*, *Molec. Medicine* 1996;2:673-691; De Strooper *et al.*, *J. Biol. Chem.* 1997;272:3590-3598; Lehmann *et al.*, *J. Biol. Chem.* 1997;272:12047-12051; Li *et al.*, *Cell* 1997;90:917-927). Structural studies predict that the presenilins contain between six and eight transmembrane (TM) domains organized such that the N-terminus, the C-terminus, and a large hydrophilic loop following the sixth TM domain are located in the cytoplasm or nucleoplasm, while the hydrophilic loop between TM1 and TM2 is located within the lumen of membranous intracellular organelles (Doan *et al.*, 1996; De Strooper *et al.*, 1997; Lehmann *et al.*, 1997).

Missense mutations in the PS1 and PS2 genes are associated with the inherited forms of early-onset AD (Sherrington *et al.*, *Nature* 1995;375:754-760; Rogaev, *et al.*, *Nature* 1995;376:775-778; Levy-Lahad *et al.*, *Science* 1995;269:970-973). Several lines of evidence have also suggested roles in developmental, apoptotic signalling and in the regulation of proteolytic cleavage of the β -amyloid precursor protein (β APP) (Levitan *et al.*, *Nature* 1995;377:351-354; Wong *et al.*, *Nature* 1997;387:288-292; Shen *et al.*, *Cell* 1997;89:629-639; Wolozin *et al.*, *Science* 1996;274:1710-1713; De Strooper *et al.*, *Nature* 1998;391:387-390). Nevertheless, it remains unclear just how these putative functions are mediated, or how they relate to the abnormal metabolism of the β APP associated with PS1 and PS2 mutations (Martin *et al.*, *NeuroReport* 1995;7:217-220; Scheuner *et al.*, *Nature Med.* 1996;2:864-870; Citron *et al.*, *Nature Med.* 1997;3:67-72; Duff *et al.*, *Nature* 1996;383:710-713; Borchelt *et al.*, *Neuron* 1996;17:1005-1013).

PS1 and PS2 interact specifically with at least two members of the *armadillo* family of proteins; neuronal plakophilin-related armadillo protein (Paffenholtz *et al.*, *Differentiation* 1997; 61: 293-304; Paffenholtz *et al.*, *Exp Cell Res* 1999; 250: 452-464; Zhou *et al.*, *Neuroreport* 1997; 8: 2085-2090) and β -catenin, that are expressed in both embryonic and post-natal tissues. Moreover, the domains of PS1 and PS2 that interact with these proteins have

been identified. Mutations in PS1 and PS2 affect the translocation of β -catenin into the nucleus of both native cells and cells transfected with a mutant PS gene. These interactions and effects are described in detail in co-pending commonly assigned U.S. Application Serial No. 09/227,725, filed January 8, 1999, the disclosure of which is incorporated herein by reference.

The identification and cloning of normal as well as mutant PS1 and PS2 genes and gene products are described in detail in co-pending commonly assigned US Application Serial Nos. 08/431,048, filed April 28, 1995; 08/496,841, filed June 28, 1995; 08/509,359, filed July 31, 1995; and 08/592,541, filed January 26, 1996, the disclosures of which are incorporated herein by reference.

There is speculation that onset of AD may be associated with aberrant interactions between mutant presenilin proteins and normal forms of PS-interacting proteins, and these changes may increase or decrease interactions present with normal PS1, or cause interaction with a mutation-specific PS-interacting protein. Such aberrant interactions also may result from normal presenilins binding to mutant forms of the PS-interacting proteins. Therefore, mutations in the PS-interacting proteins may also be implicated in the development of AD.

While the identification of normal and mutant forms of PS proteins has greatly facilitated development of diagnostics and therapeutics, a need exists for new methods and reagents to more accurately and effectively diagnose and treat AD. In addition, further insights into PS proteins and their interaction with other components may lead to new diagnostic and treatment methods for other related CNS diseases.

SUMMARY OF THE INVENTION

Applicants have discovered that PS1 and PS2 interact specifically with a transmembrane protein, herein referred to as "Presenilin Associated Membrane Protein" or "PAMP", which is expressed in multiple tissues (e.g., brain, kidney, lung, etc.). The product of this gene is therefore implicated in the biochemical pathways affected in Alzheimer's Disease, and may also have a role in other dementias, amyloid angiopathies, and developmental disorders such as spina bifida. This gene, therefore, presents a new therapeutic target for the treatment of Alzheimer's Disease and other neurologic diseases. In addition, PAMP nucleic acids, proteins and peptides,

antibodies to PAMP, cells transformed with PAMP nucleic acids, and transgenic animals altered with PAMP nucleic acids that possess various utilities, as described herein for the diagnosis, therapy and continued investigation of Alzheimer's Disease and other neurodegenerative disorders.

- 5 Furthermore, mutant PAMP nucleic acids, proteins, or peptides, cells transfected with vectors comprising mutant PAMP nucleic acids, transgenic animals expressing mutant PAMP or peptides thereof, and their use in studying Alzheimer's Disease and other neurodegenerative disorders, or developing improved diagnostic or therapeutic methods for such disorders, are presented herein.

- 10 Thus, the invention provides isolated and purified presenilin associated membrane protein (PAMP), or a functional fragment thereof, as well as nucleic acids encoding a PAMP. Preferred nucleotide and amino acid sequences are provided herein. The invention further provides probes and primers for PAMP genes. Preferred embodiments include sequences of at least 10, 15 or 20 consecutive nucleotides selected from the disclosed sequences.

- 15 The invention also provides isolated and purified mutant PAMP, or a functional fragment thereof, as well as nucleic acids encoding a mutant PAMP, and probes and primers for PAMP genes. Preferred nucleotide and amino acid sequences are provided herein.

- 20 Using the nucleic acid and amino acid sequences disclosed herein, methods for identifying allelic variants or heterospecific homologues of a human PAMP and gene are provided. The methods may be practiced using nucleic acid hybridization or amplification techniques, immunochemical techniques, or any other technique known in the art. The allelic variants may include other normal human alleles as well as mutant alleles of PAMP genes which may be causative of Alzheimer's Disease or other CNS diseases. The heterospecific homologues may be from other mammalian species, such as mice, rats, dogs, cats or non-human primates, or may be from invertebrate species, such as *Drosophila melanogaster* or *Caenorhabditis elegans*. Thus, it is another object of the invention to provide nucleic acids that encode allelic or heterospecific variants of the disclosed sequences, as well as the allelic or heterospecific proteins encoded by them.

- 30 The invention also provides vectors, and particularly expression vectors (e.g., cos-Tet vector), which include any of the above-described

nucleic acids. It is a further object of the invention to provide vectors in which normal or mutant PAMP nucleic acid sequences are operably joined to exogenous regulatory regions to produce altered patterns of expression, or to exogenous coding regions to produce fusion proteins. Conversely, it is another object to provide nucleic acids in which PAMP regulatory regions are operably joined to exogenous coding regions, including standard marker genes, to produce constructs in which the regulation of PAMP genes may be studied and used in assays or therapeutics.

The invention further provides host cells and transgenic animals transformed with any of the above-described nucleic acids of the invention. The host cells may be prokaryotic or eukaryotic cells and, in particular, may be gametes, zygotes, fetal cells, or stem cells useful in producing transgenic animal models. In one embodiment, the transgenic animal contains a transgene encoding a normal or mutant PAMP, which is expressed in neural cells such that expression can be detected, e.g., by detecting PAMP, mRNA, or protein, and more preferably by detecting a neuroprotective or a neurodegenerative phenotype. For example, the animal might manifest one or more symptoms of a neurodegenerative disease. The animal may be a vertebrate or an invertebrate. In a preferred embodiment, the transgenic animal is a mouse, and the transgene encodes a human PAMP. The transgenic animal may further comprise a second transgene encoding a normal or mutant PS1, PS2, or β APP.

In another embodiment, the invention provides an animal containing a nucleic acid that expresses a PAMP or a mutant PAMP at a higher or lower level relative to the expression level in a wild-type animal. The animal may be prepared by homologous recombination-mediated targeting of endogenous PAMP nucleic acid. In a preferred embodiment, the animal is prepared by translocation of P-elements or chemical mutagenesis.

The invention also provides a reconstituted system for measuring PAMP activity, comprising PAMP, a mutant PAMP, or functional fragments thereof, and a PAMP substrate. The reconstituted system may be a whole cell. Preferably, the whole cell contains a first nucleic acid that expresses said PAMP and a second nucleic acid that expresses the substrate. Preferably, the substrate comprises PS1 protein, PS2 protein, β APP, or a surrogate synthetic substrate protein such as Notch, which undergoes proteolytic processing events similar to those of β APP (Haass C

and Selkoe DJ. Nature 1998; 391: 387-390; De Strooper B, *et al.*, Nature 1999; 398:518-522; Song W, *et al.*, Proc Natl Acad Sci USA 1999; 96: 6959-6963.; Struhl G and Greenwald I, Nature 1999; 398: 522-525; Ye Y, *et al.*, Nature 1999; 398: 525-529.).

5 The invention provides, in addition, a complex between a PAMP, or a mutant PAMP, and an agent which provides a detectable conformational or functional change in the PAMP upon interaction with a substance being analyzed for activity against a neurodegenerative disease. The complex may further comprise PS1 protein, PS2 protein or β APP.

10 The invention also provides a method for detecting a mutation in PAMP associated with Alzheimer's or a related neurological disorder, comprising obtaining a nucleic acid sample from an individual diagnosed with or suspected of having a neurodegenerative disorder, and sequencing a gene encoding PAMP from said sample.

15 The invention also provides a method for diagnosing individuals predisposed to or having a neurodegenerative disorder, comprising obtaining a nucleic acid sample from an individual diagnosed with or suspected of having a neurodegenerative disorder, and sequencing a gene encoding PAMP from said sample.

20 The invention also provides a method for diagnosing individuals predisposed to or having a neurodegenerative disorder, comprising obtaining cells that contain nucleic acid encoding PAMP, and under non-pathological conditions, transcribe the nucleic acid, and measuring a level of transcriptional activity of the nucleic acid.

25 The invention further provides a method for diagnosing individuals predisposed to or having a neurodegenerative disorder, comprising obtaining cells from an individual that express nucleic acid encoding PAMP, or isolating PAMP from said individual, and measuring PAMP activity, for example PAMP expression levels. In an alternative
30 embodiment, the activity or abundance of a PAMP substrate may be measured.

 The invention also provides a method for identifying putative agents having anti-neurodegenerative activity, comprising administering one or more putative agents to a transgenic animal and detecting a change in
35 PAMP activity.

The invention also provides a method for identifying putative agents having anti-neurodegenerative activity, comprising adding one or more said agents to the reconstituted system described above, and detecting a change in PAMP activity.

- 5 The invention also provides a method for identifying putative agents having anti-neurodegenerative activity, comprising adding one or more said agents to the complex described above, and detecting a conformational change in PAMP.

- 10 The invention also provides a method for identifying proteins that interact with PAMP, comprising contacting said substance with the reconstituted system discussed above, and detecting a change in PAMP activity.

- 15 Further the invention provides for a method for identifying substances that modulate PAMP activity, comprising contacting a sample containing one or more substances with PAMP, or a PAMP mutant, or functional fragments thereof, and a PAMP substrate, measuring PAMP activity, and determining whether a change in PAMP activity occurs. In a preferred embodiment, the substance is a PAMP inhibitor. In another preferred embodiment, the substance stimulates PAMP activity.

- 20 These and other aspects of the invention are further elaborated in the Detailed Description of the Invention and Examples, *infra*.

DESCRIPTION OF THE DRAWINGS

- 25 FIGURE 1A and 1B. Predicted amino acid sequences for human (SEQ ID NO:14), mouse (SEQ ID NO:16), *D.melanogaster* (SEQ ID NO:18) and *C.elegans* (SEQ ID NO:12) orthologues. Residues not conserved in non-human PAMP are blank, conserved residues are aligned, similar residues are denoted by "+".

30 DETAILED DESCRIPTION OF THE INVENTION

- While PS1 and PS2 have been implicated in proper processing of β APP, and mutations in these proteins have been associated with Alzheimer's Disease, further understanding of the development and progression of this disease, as well as other neurodegenerative diseases,
35 requires a more complete understanding of the functions of the presenilins

and other proteins with which they interact. The present invention advantageously identifies such a protein.

PAMP

5 The invention is based, in part, on the discovery of a novel Type I transmembrane protein that interacts with PS1 and PS2, and with the α - and β -secretase derived fragments of β APP. The protein has been termed "Presenilin Associated Membrane Protein" (PAMP). As referred to herein, "PAMP" means a native or mutant full-length protein, or fragments thereof,
10 that interacts with the PAMP-interacting domain of a presenilin protein. PAMP is also known under the name "Nicastrin". Human, murine, *D. melanogaster* and *C. elegans* orthologues are provided.

 Experimental data indicate that PAMP, PS1, and PS2 exist in the same high molecular weight protein complex, and PAMP and PS1 are
15 both co-localized to intracellular membranes in the endoplasmic reticulum and Golgi apparatus. Abolition of functional expression of a *C. elegans* homologue of this protein leads to the development of *Notch*-like developmental defects. This shows that PAMP is also intimately involved in the processing of not only β APP, but also other molecules, such as *Notch* and its homologues. From
20 expressed sequence tags (EST) databases, it is apparent that, like PS1 and PS2, PAMP is expressed in multiple tissues.

 Various structural features characterize PAMP (GenBank; Accession No. Q92542; SEQ ID NO: 14). The nucleotide sequence (SEQ ID NO: 13) of human PAMP predicts that the gene encodes a Type 1
25 transmembrane protein of 709 amino acids (SEQ ID NO: 14), the protein having a short hydrophilic C-terminus (~20 residues), a hydrophobic transmembrane domain (15-20 residues), and a longer N-terminal hydrophilic domain which contains several potentially functional sequence motifs as listed below in Table 1. The PAMP sequence also contains a Trp-Asp (WD) repeat
30 (residue 226), at least one "DTG" motif (residues 91 - 93) present in eukaryotic aspartyl proteases, as well as several "DTA/DTAE" motifs (residues 480 - 482, 504 - 506) present in viral aspartyl proteases. There are also four conserved cysteine residues in the N-terminal hydrophilic domain (Cys₁₉₅, Cys₂₁₃, Cys₂₃₀, and Cys₂₄₈ in human PAMP) having a periodocity of
35 16-17 residues, which may form a functional domain (e.g., a metal binding domain or disulfide bridge for tertiary structure stabilization). Subdomains of

PAMP have weak homologies to a variety of peptidases. For example, residues 322 - 343, 361- 405, and 451 - 466 have 46% ($p = 0.03$) similarity to another hypothetical protein, *C. elegans* aminopeptidase hydrolase precursor signal antigen transmembrane receptor zinc glycoprotein (SWISS-PROT; 5 www.expasy.ch/sprot; Accession No. Q93332).

Table 1 - Potential functional sequence motifs in PAMP (SEQ ID NO: 14).

Potential function	PAMP Residue
N-asparaginyl glycosylation	44, 101, 290, 492, 698, 964, 1353, 1772, 2209, 2675, 3183, 3715, 4279, 4854, 5436, and 6050.
Glycosaminoglycan attachment	403
Myristolation	4, 37, 102, 226, 376, 548, 757, 1055, 1497, 1947, 2455, and 3035.
Phosphorylation sites for cAMP- and cGMP-dependent protein kinase	231
Phosphorylation sites for protein kinase C	114, 383, 724, 1109, 1499, 1983, 2598, and 3223
Phosphorylation sites for casein kinase II	7, 289, 652, 1026, 1483, 1951, 2425, 3068, and 3717

- The invention is further based on the identification of conserved functional domains, based on comparison and evaluation of the predicted amino acid sequences of human (SEQ ID NO: 14), murine (SEQ ID NO: 16), *D. melanogaster* (SEQ ID NO: 18), and *C. elegans* (SEQ ID NO: 12) orthologues of PAMP. "PAMP" can be characterized by the presence of conserved structural features, relative to orthologues from *D. melanogaster* and *C. elegans*. Nucleotide sequences encoding homologous hypothetical proteins exist in mice multiple EST, and *C. elegans* (GenBank; www.ncbi.nlm.nih.gov; Accession No. Z75714; 37% similarity, $p = 8.7e^{-26}$) (Wilson *et al.*, *Nature* 1994; 368: 32-38). These hypothetical murine and nematode proteins have a similar topology and contain similar functional motifs to human PAMP. The existence of such homology predicts that similar proteins will be detected in other species including *Xenopus*, and Zebra fish, to mention a few such possibilities. By comparing the predicted amino acid sequences of human (SEQ ID NO: 14), murine (SEQ ID NO: 16), *D. melanogaster* (SEQ ID NO: 18), and *C. elegans* (SEQ ID NO: 12) PAMP proteins, we have deduced a series of conserved functional domains. One domain has chemical similarities to cyclic nucleotide binding domains of other proteins, and may have some regulatory role on a potential complex formed between PS1:PAMP and the C-terminal fragment of β APP, derived either from α - or β -secretase. These putative functional domains are sites for therapeutic

target development by deploying drugs which might interact with these sites to modulate β APP processing via this complex.

The term "PAMP" also refers to functionally active fragments of the protein. Such fragments include, but are not limited to, peptides that
5 contain an epitope, e.g., as determined by conventional algorithms such as hydrophilicity/hydrophobicity analysis for antibody epitopes, and amphipathicity or consensus algorithms for T cell epitopes (Spouge, *et al.*, J. Immunol, 138:2204, 1987; Margalit, *et al.*, J. Immunol., 138:2213, 1987; Rothbard, Ann. Inst. Pateur., 137E:518, 1986; Rothbard and Taylor, EMBO J.;
10 7:93, 1988). More preferably, a functionally active fragment of PAMP is a conserved domain, relative to the *D. melanogaster* and *C. elegans* orthologues. A specific functionally active fragment of PAMP is a fragment that interacts with PS1 or PS2, or both.

PAMP also encompasses naturally occurring variants, including
15 other mammalian PAMPs (readily identified, as shown herein for murine PAMP, based on the presence of the structural features set forth above), allelic variants of PAMP from other human sources (including variants containing polymorphisms that are predictive of disease propensity or of response to pharmacological agents), and mutant forms of PAMP or *PAMP*
20 genes that are associated with neurological diseases and disorders (such as spina bifida), particularly neurodegenerative diseases (such as AD). Also included are artificial PAMP mutants created by standard techniques such as site directed mutagenesis or chemical synthesis.

A PAMP "substrate" may be a polypeptide or protein, or any
25 other type of compound, with which PAMP interacts physiologically. Examples of PAMP substrates include PS1, PS2, and β APP. Furthermore, a PAMP "ligand" may be a polypeptide, protein, lipid, carbohydrate, vitamin, mineral, amino acid, or any other type of compound which binds to PAMP. Hypothetically, PAMP may function as a receptor which modulates
30 PS1/PS2/ β APP processing in response to signal (ligand) dependent interactions with PAMP.

Definitions

In accordance with the present invention there may be
35 employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully

- in the literature. See, e.g., Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (herein "Sambrook et al., 1989"); *DNA Cloning: A Practical Approach*, Volumes I and II (D.N. Glover ed. 1985);
- 5 *Oligonucleotide Synthesis* (M.J. Gait ed. 1984); *Nucleic Acid Hybridization* (B.D. Hames & S.J. Higgins eds. (1985)); *Transcription And Translation* (B.D. Hames & S.J. Higgins, eds. (1984)); *Animal Cell Culture* (R.I. Freshney, ed. (1986)); *Immobilized Cells And Enzymes* (IRL Press, (1986)); B. Perbal, *A Practical Guide To Molecular Cloning* (1984); F.M. Ausubel et al. (eds.),
- 10 *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc. (1994).

If appearing herein, the following terms shall have the definitions set out below.

- The use of italics (e.g., *PAMP*) indicates a nucleic acid molecule (cDNA, mRNA, gene, etc.); normal text (e.g., PAMP) indicates the polypeptide
- 15 or protein.

- In a specific embodiment, the term "about" or "approximately" means within 20%, preferably within 10%, and more preferably within 5% of a given value or range. Alternatively, particularly in biological systems which are often responsive to order of magnitude changes, the term about means
- 20 within an order of magnitude of a given value, preferably within a multiple of about 5-fold, and more preferably within a factor of about 2-fold of a given value.

- As used herein, the term "isolated" means that the referenced material is free of components found in the natural environment in which the
- 25 material is normally found. In particular, isolated biological material is free of cellular components. In the case of nucleic acid molecules, an isolated nucleic acid includes a PCR product, an isolated mRNA, a cDNA, or a restriction fragment. In another embodiment, an isolated nucleic acid is preferably excised from the chromosome in which it may be found, and more
- 30 preferably is no longer joined to non-regulatory, non-coding regions, or to other genes, located upstream or downstream of the gene contained by the isolated nucleic acid molecule when found in the chromosome. In yet another embodiment, the isolated nucleic acid lacks one or more introns. Isolated nucleic acid molecules can be inserted into plasmids, cosmids, artificial
- 35 chromosomes, and the like. Thus, in a specific embodiment, a recombinant nucleic acid is an isolated nucleic acid. An isolated protein may be associated

with other proteins or nucleic acids, or both, with which it associates in the cell, or with cellular membranes if it is a membrane-associated protein. An isolated organelle, cell, or tissue is removed from the anatomical site in which it is found in an organism. An isolated material may be, but need not be, purified.

The term "purified" as used herein refers to material that has been isolated under conditions that reduce or eliminate unrelated materials, *i.e.*, contaminants. For example, a purified protein is preferably substantially free of other proteins or nucleic acids with which it is associated in a cell; a purified nucleic acid molecule is preferably substantially free of proteins or other unrelated nucleic acid molecules with which it can be found within a cell.

As used herein, the term "substantially free" is used operationally, in the context of analytical testing of the material. Preferably, purified material substantially free of contaminants is at least 50% pure; more preferably, at least 90% pure, and more preferably still at least 99% pure. Purity can be evaluated by chromatography, gel electrophoresis, immunoassay, composition analysis, biological assay, and other methods known in the art.

The term "host cell" means any cell of any organism that is selected, modified, transformed, grown, or used or manipulated in any way, for the production of a substance by the cell, for example the expression by the cell of a gene, a DNA or RNA sequence, a protein or an enzyme. Host cells can further be used for screening or functional assays, as described *infra*. A host cell has been "transfected" by exogenous or heterologous DNA when such DNA has been introduced inside the cell. A cell has been "transformed" by exogenous or heterologous DNA when the transfected DNA is expressed and effects a function or phenotype on the cell in which it is expressed. The term "expression system" means a host cell transformed by a compatible expression vector and cultured under suitable conditions *e.g.* for the expression of a protein coded for by foreign DNA carried by the vector and introduced to the host cell.

Proteins and polypeptides can be made in the host cell by expression of recombinant DNA. As used herein, the term "polypeptide" refers to an amino acid-based polymer, which can be encoded by a nucleic acid or prepared synthetically. Polypeptides can be proteins, protein fragments, chimeric proteins, etc. Generally, the term "protein" refers to a

polypeptide expressed endogenously in a cell, e.g., the naturally occurring form (or forms) of the amino acid-based polymer.

5 A "coding sequence" or a sequence "encoding" an expression product, such as a RNA, polypeptide, protein, or enzyme, is a nucleotide sequence that, when expressed, results in the production of that RNA, polypeptide, protein, or enzyme, i.e., the nucleotide sequence encodes an amino acid sequence for that polypeptide, protein or enzyme. A coding sequence for a protein may include a start codon (usually ATG) and a stop codon.

10 The coding sequences herein may be flanked by natural regulatory (expression control) sequences, or may be associated with heterologous sequences, including promoters, internal ribosome entry sites (IRES) and other ribosome binding site sequences, enhancers, response elements, suppressors, signal sequences, polyadenylation sequences, 15 introns, 5'- and 3'- non-coding regions, and the like. The nucleic acids may also be modified by many means known in the art. Non-limiting examples of such modifications include methylation, "caps", substitution of one or more of the naturally occurring nucleotides with an analog, and internucleotide modifications.

20 The term "gene", also called a "structural gene" means a DNA sequence that codes for or corresponds to a particular sequence of ribonucleic acids or amino acids which comprise all or part of one or more proteins, and may or may not include regulatory DNA sequences, such as promoter sequences, which determine for example the conditions under which 25 the gene is expressed.

A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the 30 transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background.

A coding sequence is "under the control" or "operatively associated with" of transcriptional and translational control sequences in a cell 35 when RNA polymerase transcribes the coding sequence into mRNA, which

then may be trans-RNA spliced (if it contains introns) and translated into the protein encoded by the coding sequence.

5 The terms "express" and "expression" mean allowing or causing the information in a gene or DNA sequence to become manifest, for example producing a protein by activating the cellular functions involved in transcription and translation of a corresponding gene or DNA sequence. A DNA sequence is expressed in or by a cell to form an "expression product" such as a protein. The expression product itself, e.g. the resulting protein, may also be said to be "expressed" by the cell.

10 The term "transfection" means the introduction of a foreign nucleic acid into a cell. The term "transformation" means the introduction of a "foreign" (i.e. extrinsic or extracellular) gene, DNA or RNA sequence to a host cell, so that the host cell will express the introduced gene or sequence to produce a desired substance, typically a protein or enzyme coded by the introduced gene or sequence. The introduced gene or sequence may also be called a "cloned", "foreign", or "heterologous" gene or sequence, and may include regulatory or control sequences used by a cell's genetic machinery. The gene or sequence may include nonfunctional sequences or sequences with no known function. A host cell that receives and expresses introduced DNA or RNA has been "transformed" and is a "transformant" or a "clone." 20 The DNA or RNA introduced to a host cell can come from any source, including cells of the same genus or species as the host cell, or cells of a different genus or species.

The terms "vector", "cloning vector" and "expression vector" 25 mean the vehicle by which a DNA or RNA sequence (e.g., a foreign gene) can be introduced into a host cell, so as to transform the host and promote expression (e.g., transcription and translation) of the introduced sequence. Vectors include plasmids, phages, viruses, etc. A "cassette" refers to a DNA coding sequence or segment of DNA that codes for an expression product that can be inserted into a vector at defined restriction sites. The cassette 30 restriction sites are designed to ensure insertion of the cassette in the proper reading frame. Generally, foreign DNA is inserted at one or more restriction sites of the vector DNA, and then is carried by the vector into a host cell along with the transmissible vector DNA. A segment or sequence of DNA having inserted or added DNA, such as an expression vector, can also be called a 35 "DNA construct." Recombinant cloning vectors will often include one or more

replication systems for cloning or expression, one or more markers for selection in the host, e.g. antibiotic resistance, and one or more expression cassettes.

5 A "knockout mammal" is a mammal (e.g., mouse) that contains within its genome a specific gene that has been inactivated by the method of gene targeting (see, e.g., US Patents No. 5,777,195 and No. 5,616,491). A knockout mammal includes both a heterozygote knockout (*i.e.*, one defective allele and one wild-type allele) and a homozygous mutant. Preparation of a knockout mammal requires first introducing a nucleic acid construct that will
10 be used to suppress expression of a particular gene into an undifferentiated cell type termed an embryonic stem cell. This cell is then injected into a mammalian embryo. A mammalian embryo with an integrated cell is then implanted into a foster mother for the duration of gestation. Zhou, *et al.* (Genes and Development, 9:2623-34, 1995) describes PPCA knock-out mice.
15 Knockout mice can be used to study defects in neurological development or neurodegenerative diseases. Disease phenotypes that develop can provide a platform for further drug discovery.

The term "knockout" refers to partial or complete suppression of the expression of at least a portion of a protein encoded by an endogenous
20 DNA sequence in a cell. The term "knockout construct" refers to a nucleic acid sequence that is designed to decrease or suppress expression of a protein encoded by endogenous DNA sequences in a cell. The nucleic acid sequence used as the knockout construct is typically comprised of (1) DNA from some portion of the gene (exon sequence, intron sequence, and/or promoter
25 sequence) to be suppressed and (2) a marker sequence used to detect the presence of the knockout construct in the cell. The knockout construct is inserted into a cell, and integrates with the genomic DNA of the cell in such a position so as to prevent or interrupt transcription of the native DNA sequence. Such insertion usually occurs by homologous recombination (*i.e.*,
30 regions of the knockout construct that are homologous to endogenous DNA sequences hybridize to each other when the knockout construct is inserted into the cell and recombine so that the knockout construct is incorporated into the corresponding position of the endogenous DNA). The knockout construct nucleic acid sequence may comprise 1) a full or partial sequence of one or
35 more exons and/or introns of the gene to be suppressed, 2) a full or partial promoter sequence of the gene to be suppressed, or 3) combinations thereof.

Typically, the knockout construct is inserted into an embryonic stem cell (ES cell) and is integrated into the ES cell genomic DNA, usually by the process of homologous recombination. This ES cell is then injected into, and integrates with, the developing embryo.

5 Generally, for homologous recombination, the DNA will be at least about 1 kilobase (kb) in length and preferably 3-4 kb in length, thereby providing sufficient complementary sequence for recombination when the knockout construct is introduced into the genomic DNA of the ES cell.

10 A "knock-in" mammal is a mammal in which an endogenous gene is substituted with a heterologous gene or a modified variant of the endogenous gene (Roemer *et al.*, New Biol. 3:331, 1991). Preferably, the heterologous gene is "knocked-in" to a locus of interest, for example into a gene that is the subject of evaluation of expression or function, thereby linking the heterologous gene expression to transcription from the appropriate
15 promoter (in which case the gene may be a reporter gene; see Elefanty *et al.*, Proc Natl Acad Sci USA 95:11897,1998). This can be achieved by homologous recombination, transposon (Westphal and Leder, Curr Biol 7:530, 1997), using mutant recombination sites (Araki *et al.*, Nucleic Acids Res 25:868, 1997) or PCR (Zhang and Henderson, Biotechniques 25:784, 1998).

20 The phrases "disruption of the gene" and "gene disruption" refer to insertion of a nucleic acid sequence into one region of the native DNA sequence (usually one or more exons) and/or the promoter region of a gene so as to decrease or prevent expression of that gene in the cell as compared to the wild-type or naturally occurring sequence of the gene. By way of
25 example, a nucleic acid construct can be prepared containing a DNA sequence encoding an antibiotic resistance gene which is inserted into the DNA sequence that is complementary to the DNA sequence (promoter and/or coding region) to be disrupted. When this nucleic acid construct is then transfected into a cell, the construct will integrate into the genomic DNA.
30 Thus, some progeny of the cell will no longer express the gene, or will express it at a decreased level, as the DNA is now disrupted by the antibiotic resistance gene.

 The term "heterologous" refers to a combination of elements not naturally occurring. For example, heterologous DNA refers to DNA not
35 naturally located in the cell, or in a chromosomal site of the cell. Preferably, the heterologous DNA includes a gene foreign to the cell. A heterologous

expression regulatory element is a such an element operatively associated with a different gene than the one it is operatively associated with in nature. In the context of the present invention, an gene is heterologous to the recombinant vector DNA in which it is inserted for cloning or expression, and it is heterologous to a host cell containing such a vector, in which it is expressed, e.g., a CHO cell.

The terms "mutant" and "mutation" mean any detectable change in genetic material, e.g. DNA, or any process, mechanism, or result of such a change. This includes gene mutations, in which the structure (e.g., DNA sequence) of a gene is altered, any gene or DNA arising from any mutation process, and any expression product (e.g., protein) expressed by a modified gene or DNA sequence. The term "variant" may also be used to indicate a modified or altered gene, DNA sequence, enzyme, cell, etc., i.e., any kind of mutant.

"Sequence-conservative variants" of a polynucleotide sequence are those in which a change of one or more nucleotides in a given codon position results in no alteration in the amino acid encoded at that position.

"Function-conservative variants" are those in which a given amino acid residue in a protein or enzyme has been changed without altering the overall conformation and function of the polypeptide, including, but not limited to, replacement of an amino acid with one having similar properties (such as, for example, polarity, hydrogen bonding potential, acidic, basic, hydrophobic, aromatic, and the like). Amino acids with similar properties are well known in the art. For example, arginine, histidine and lysine are hydrophilic-basic amino acids and may be interchangeable. Similarly, isoleucine, a hydrophobic amino acid, may be replaced with leucine, methionine or valine. Such changes are expected to have little or no effect on the apparent molecular weight or isoelectric point of the protein or polypeptide. Amino acids other than those indicated as conserved may differ in a protein or enzyme so that the percent protein or amino acid sequence similarity between any two proteins of similar function may vary and may be, for example, from 70% to 99% as determined according to an alignment scheme such as by the Cluster Method, wherein similarity is based on the MEGALIGN algorithm. A "function-conservative variant" also includes a polypeptide or enzyme which has at least 60 % amino acid identity as determined by BLAST (Altschul SF, *et al.*, J Mol Biol 1990; 215: 403-410) or

FASTA algorithms, preferably at least 75%, most preferably at least 85%, and even more preferably at least 90%, and which has the same or substantially similar properties or functions as the native or parent protein or enzyme to which it is compared.

5 An "ortholog" to a protein means a corresponding protein from another species. Orthologous proteins typically have similar functions in different species, and can also be substantially homologous.

 As used herein, the term "homologous" in all its grammatical forms and spelling variations refers to the relationship between proteins that
10 possess a "common evolutionary origin," including proteins from superfamilies (e.g., the immunoglobulin superfamily) and homologous proteins from different species (e.g., myosin light chain, etc.) (Reeck *et al.*, Cell 50:667, 1987). Such proteins (and their encoding genes) have sequence homology, as reflected by their sequence similarity, whether in terms of percent similarity
15 or the presence of specific residues or motifs. Motif analysis can be performed using, for example, the program BLOCKS (www.blocks.fhcrc.org).

 Accordingly, the term "sequence similarity" in all its grammatical forms refers to the degree of identity or correspondence between nucleic acid or amino acid sequences of proteins that may or may not share a common
20 evolutionary origin (see Reeck *et al.*, *supra*). However, in common usage and in the instant application, the term "homologous," when modified with an adverb such as "highly," may refer to sequence similarity and may or may not relate to a common evolutionary origin.

 In a specific embodiment, two DNA sequences are "substantially
25 homologous" or "substantially similar" when at least about 80%, and most preferably at least about 90 or 95% of the nucleotides match over the defined length of the DNA sequences, as determined by sequence comparison algorithms, such as BLAST, FASTA, DNA Strider, etc. Sequences that are substantially homologous can be identified by comparing the sequences using
30 standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system.

 Similarly, in a particular embodiment, two amino acid sequences are "substantially homologous" or "substantially similar" when greater than
35 80% of the amino acids are identical, or greater than about 90% are similar (functionally identical). Preferably, the similar or homologous sequences are

identified by alignment using, for example, the GCG (Genetics Computer Group, Program Manual for the GCG Package, Version 7, Madison, Wisconsin) pileup program, ProteinPredict (dodo.cmpc.columbia.edu/predictprotein), or any of the programs described above (BLAST, FASTA, etc.).

A nucleic acid molecule is "hybridizable" to another nucleic acid molecule, such as a cDNA, genomic DNA, or RNA, when a single stranded form of the nucleic acid molecule can anneal to the other nucleic acid molecule under the appropriate conditions of temperature and solution ionic strength (see Sambrook *et al.*, *supra*). The conditions of temperature and ionic strength determine the "stringency" of the hybridization. For preliminary screening for homologous nucleic acids, low stringency hybridization conditions, corresponding to a T_m (melting temperature) of 55°C, can be used. Moderate stringency hybridization conditions correspond to a higher T_m and high stringency hybridization conditions correspond to the highest T_m . Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of T_m for hybrids of nucleic acids having those sequences. The relative stability (corresponding to higher T_m) of nucleic acid hybridizations decreases in the following order: RNA:RNA, DNA:RNA, DNA:DNA. For hybrids of greater than 100 nucleotides in length, equations for calculating T_m have been derived (see Sambrook *et al.*, *supra*, 9.50-9.51). For hybridization with shorter nucleic acids, *i.e.*, oligonucleotides, the position of mismatches becomes more important, and the length of the oligonucleotide determines its specificity (see Sambrook *et al.*, *supra*, 11.7-11.8). A minimum length for a hybridizable nucleic acid is at least about 10 nucleotides; preferably at least about 15 nucleotides; and more preferably the length is at least about 20 nucleotides.

The present invention provides antisense nucleic acids (including ribozymes), which may be used to inhibit expression of PAMP, *e.g.*, to disrupt a cellular process (such disruption can be used in an animal model or therapeutically). An "antisense nucleic acid" is a single stranded nucleic

acid molecule which, on hybridizing under cytoplasmic conditions with complementary bases in an RNA or DNA molecule, inhibits the latter's role. If the RNA is a messenger RNA transcript, the antisense nucleic acid is a countertranscript or mRNA-interfering complementary nucleic acid. As
5 presently used, "antisense" broadly includes RNA-RNA interactions, RNA-DNA interactions, ribozymes and RNase-H mediated arrest. Antisense nucleic acid molecules can be encoded by a recombinant gene for expression in a cell (e.g., U.S. Patent No. 5,814,500; U.S. Patent No. 5,811,234), or alternatively they can be prepared synthetically (e.g., U.S. Patent No.
10 5,780,607).

As used herein, the term "oligonucleotide" refers to a nucleic acid, generally of at least 10, preferably at least 15, and more preferably at least 20 nucleotides, preferably no more than 100 nucleotides, that is hybridizable to a genomic DNA molecule, a cDNA molecule, or an mRNA
15 molecule encoding a gene, mRNA, cDNA, or other nucleic acid of interest. Oligonucleotides can be labeled, e.g., with ³²P-nucleotides or nucleotides to which a label, such as biotin, has been covalently conjugated. In one embodiment, a labeled oligonucleotide can be used as a probe to detect the presence of a nucleic acid. In another embodiment, oligonucleotides (one or
20 both of which may be labeled) can be used as PCR primers, e.g., for cloning full length or a fragment of a protein or polypeptide. In a further embodiment, an oligonucleotide of the invention can form a triple helix with a nucleic acid (genomic DNA or mRNA) encoding a protein or polypeptide. Generally, oligonucleotides are prepared synthetically, preferably on a nucleic acid
25 synthesizer. Accordingly, oligonucleotides can be prepared with non-naturally occurring phosphoester analog bonds, such as thioester bonds, etc. Furthermore, the oligonucleotides herein may also be modified with a label capable of providing a detectable signal, either directly or indirectly. Exemplary labels include radioisotopes, fluorescent molecules, biotin, and the
30 like.

Specific non-limiting examples of synthetic oligonucleotides envisioned for this invention include oligonucleotides that contain phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl, or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic
35 intersugar linkages. Most preferred are those with CH₂-NH-O-CH₂, CH₂-N(CH₃)-O-CH₂, CH₂-O-N(CH₃)-CH₂, CH₂-N(CH₃)-N(CH₃)-CH₂ and O-N(CH₃)-

CH₂-CH₂ backbones (where phosphodiester is O-PO₂-O-CH₂). US Patent No. 5,677,437 describes heteroaromatic oligonucleoside linkages. Nitrogen linkers or groups containing nitrogen can also be used to prepare oligonucleotide mimics (U.S. Patents No. 5,792,844 and No. 5,783,682). US Patent No. 5,637,684 describes phosphoramidate and phosphorothioamidate oligomeric compounds. Also envisioned are oligonucleotides having morpholino backbone structures (U.S. Pat. No. 5,034,506). In other embodiments, such as the peptide-nucleic acid (PNA) backbone, the phosphodiester backbone of the oligonucleotide may be replaced with a polyamide backbone, the bases being bound directly or indirectly to the aza nitrogen atoms of the polyamide backbone (Nielsen *et al.*, Science 254:1497, 1991). Other synthetic oligonucleotides may contain substituted sugar moieties comprising one of the following at the 2' position: OH, SH, SCH₃, F, OCN, O(CH₂)_nNH₂ or O(CH₂)_nCH₃ where n is from 1 to about 10; C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkaryl or aralkyl; Cl; Br; CN; CF₃; OCF₃; O-; S-, or N-alkyl; O-, S-, or N-alkenyl; SOCH₃; SO₂CH₃; ONO₂; NO₂; N₃; NH₂; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; a fluorescein moiety; an RNA cleaving group; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. Oligonucleotides may also have sugar mimetics such as cyclobutyls or other carbocyclics in place of the pentofuranosyl group. Nucleotide units having nucleosides other than adenosine, cytidine, guanosine, thymidine and uridine, such as inosine, may be used in an oligonucleotide molecule.

Presenilin Interacting Proteins

Mutant PS1 and PS2 genes, and their corresponding amino acid sequences are described in Applicants' co-pending U.S. Application Serial No. 08/888,077, filed July 3, 1997, and incorporated herein by reference. Examples of PS1 mutations include I143T, M146L, L171P, F177S, A260V, C263R, P264L, P267S, E280A, E280G, A285V, L286V, Δ291-319, L322V, G384A, L392V, C410Y and I439V. Examples of PS2 mutations include N141I, M239V and I420T.

The methods of the present invention are not limited to mutant presenilins wherein the PAMP-interacting domain is mutated relative to the

wild-type protein. For example, Applicants have observed that mutations in PS1 (e.g., M146L) outside of the interacting domain (loop) also affect β -catenin translocation. These mutations probably disturb the presenilin *armadillo* interactions by altering the function of a high MW complex which contains, e.g., the presenilin and *armadillo* proteins, as described in Yu *et al.*, 1998, *J. Biol. Chem.* 273:16460-16475. Moreover, a comparison of the human PS1 (hPS1) and PS2 (hPS2) sequences reveals that these pathogenic mutations are in regions of the PS1 protein which are conserved in the PS2 protein. Therefore, corresponding mutations in corresponding regions of PS2 may also be expected to be pathogenic and are useful in the methods described herein.

Proteins that interact with the presenilins, i.e., PS-interacting proteins, include PAMP, the S5a subunit of the 26S proteasome (GenBank; Accession No. U51007), Rab11 (GenBank; Accession Nos. X56740 and X53143), retinoid X receptor B, also known as nuclear receptor co-regulator or MHC (GenBank Accession Nos. M84820, and X63522), GT24 (GenBank Accession No. U81004), β -catenin (Zhou *et al.*, 1997, *Neuro. Report* (Fast Track) 8:1025-1029 and Yu *et al.*, *supra*) as well as *armadillo* proteins. These and other PS1 binding proteins are described in Applicants' copending commonly assigned U.S. Application Serial No. 08/863,077, filed July 3, 1997, as well as U.S. Application Serial No. 08/592,541, filed January 26, 1996, the disclosures of which are incorporated herein by reference.

PAMP Mutants

PAMP mutants may cause biochemical changes similar to those affecting the onset or progression of Alzheimer Disease. Therefore, artificial PAMP mutations can potentially be used to generate cellular and other model systems to design treatments and preventions for Alzheimer Disease related disorders. Such mutations may also be used for evaluating whether PAMP is involved in the pathogenesis of AD. Since the amyloid- β (A β) inducing mutations are found in amino acid residues of a soluble (non-membrane spanning) domain of PAMP, analysis of the normal structure of this domain and the effects of these and other nearby mutations on the structure of this domain (and the other domains of PAMP) provide information for the design of specific molecular therapeutics.

- In general, modifications of the sequences encoding the polypeptides described herein may be readily accomplished by standard techniques such as chemical syntheses and site-directed mutagenesis. See Gillman et al., 1979, *Gene* 8:81-97; Roberts et al., 1987, *Nature* 328:731-734; and Innis (ed.), 1990, *PCR Protocols: A Guide to Methods and Applications*, Academic Press, New York. Most modifications are evaluated by routine screening via an assay designed to select for the desired property.

Antibodies to PAMP

- According to the invention, PAMP polypeptides produced recombinantly or by chemical synthesis, and fragments or other derivatives or analogs thereof, including fusion proteins and PAMP mutants, may be used as an immunogen to generate antibodies that recognize the PAMP polypeptide. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library. Such an antibody is preferably specific for human PAMP, PAMP originating from other species, or for post-translationally modified (e.g. phosphorylated, glycosylated) PAMP.

- Various procedures known in the art may be used for the production of polyclonal antibodies to PAMP polypeptide or derivative or analog thereof. For the production of antibody, various host animals can be immunized by injection with the PAMP polypeptide, or a derivative (e.g., fragment or fusion protein) thereof, including but not limited to rabbits, mice, rats, sheep, goats, etc. In one embodiment, the PAMP polypeptide or fragment thereof can be conjugated to an immunogenic carrier, e.g., bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH). Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (*bacille Calmette-Guerin*) and *Corynebacterium parvum*. Antisera may be collected at a chosen time point after immunization, and purified as desired.

- For preparation of monoclonal antibodies directed toward the PAMP polypeptide, or fragment, analog, or derivative thereof, any technique

that provides for the production of antibody molecules by continuous cell lines in culture may be used. These include but are not limited to the hybridoma technique originally developed by Kohler and Milstein (Nature 256:495-497, 1975), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, Immunology Today 4:72, 1983; Cote *et al.*, Proc. Natl. Acad. Sci. U.S.A. 80:2026-2030, 1983), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole *et al.*, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96, 1985). Production of human antibodies by CDR grafting is described in U.S. Patent Nos. 5,585,089, 5,693,761, and 5,693,762 to Queen *et al.*, and also in U.S. Patent No. 5,225,539 to Winter and International Patent Application PCT/WO91/09967 by Adau *et al.* In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals (International Patent Publication No. WO 89/12690, published 28 December 1989). In fact, according to the invention, techniques developed for the production of "chimeric antibodies" (Morrison *et al.*, J. Bacteriol. 159:870, 1984; Neuberger *et al.*, Nature 312:604-608, 1984; Takeda *et al.*, Nature 314:452-454, 1985) by splicing the genes from a mouse antibody molecule specific for an PAMP polypeptide together with genes from a human antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention. Such human or humanized chimeric antibodies are preferred for use in therapy of human diseases or disorders (described *infra*), since the human or humanized antibodies are much less likely than xenogenic antibodies to induce an immune response, in particular an allergic response, themselves.

According to the invention, techniques described for the production of single chain antibodies (U.S. Patent Nos. 5,476,786 and 5,132,405 to Huston; U.S. Patent 4,946,778) can be adapted to produce PAMP polypeptide-specific single chain antibodies. An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries (Huse *et al.*, Science 246:1275-1281, 1989) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for an PAMP polypeptide, or its derivatives, or analogs.

Antibody fragments which contain the idiotype of the antibody molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂ fragment which can be

produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.

- 5 In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, e.g., radioimmunoassay, ELISA (enzyme-linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, *in situ* immunoassays (using colloidal
10 gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary
15 antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention. For example, to select antibodies which
20 recognize a specific epitope of an PAMP polypeptide, one may assay generated hybridomas for a product which binds to an PAMP polypeptide fragment containing such epitope. For selection of an antibody specific to an PAMP polypeptide from a particular species of animal, one can select on the basis of positive binding with PAMP polypeptide expressed by or isolated from
25 cells of that species of animal.

- The foregoing antibodies can be used in methods known in the art relating to the localization and activity of the PAMP polypeptide, e.g., for Western blotting, imaging PAMP polypeptide *in situ*, measuring levels thereof in appropriate physiological samples, etc. using any of the detection
30 techniques mentioned above or known in the art. Such antibodies can be used to identify proteins that interact with PAMP, and to detect conformational or structural changes in PAMP.

- In a specific embodiment, antibodies that agonize or antagonize the activity of PAMP polypeptide can be generated. They can also be used to
35 regulate or inhibit PAMP activity intracellular, i.e., the invention contemplates an intracellular antibody (intrabody), e.g., single chain Fv antibodies (see

The nucleotide sequence and the protein sequence and the putative biological activity of PAMP or PAMP mutants can all be used for the purposes of diagnosis of individuals who are at-risk for, or who actually have, a variety of neurodegenerative diseases (including Alzheimer's disease, Lewy body variant, Parkinson's disease-dementia complex, amyotrophic lateral sclerosis etc.), neuropsychiatric diseases (schizophrenia, depression, mild cognitive impairment, benign senescent forgetfulness, age-associated memory loss, etc.), developmental disorders associated with defects in intracellular signal transduction mediated by factors such as Notch, Delta, Wingless, etc., and neoplasms (e.g., bowel cancer, etc.) associated with abnormalities of PS1/PAMP/PS2 mediated regulation of cell death pathways. These diagnostic entities can be used by searching for alterations in: the nucleotide sequence of PAMP; in the transcriptional activity of PAMP; in the protein level as monitored by immunological means (e.g., ELISA and Western blots); in the amino acid sequence (as ascertained by Western blotting, amino acid sequence analysis, mass spectroscopy); and/or in the biological activity of the PAMP protein as measured by either *in vivo* methods (e.g., monitoring β APP processing and the production of amyloid- β peptide ($A\beta$), or other suitable protein substrates for PAMP including Notch, etc.), or by *in vitro* assays (using either whole cell or cell-free assays to measure processing of suitable substrates including β APP or parts thereof, and other proteins such as Notch). Any of these assays can also be performed in a transgenic animal model as well, e.g., to measure the effect of a drug or a mutation or overexpression of a different gene *in vivo*.

Identification and isolation of PAMP provides for development of screening assays, particularly for high throughput screening of molecules that up- or down-regulate the activity of PAMP, e.g., by permitting expression of PAMP in quantities greater than can be isolated from natural sources, or in indicator cells that are specially engineered to indicate the activity of PAMP

expressed after transfection or transformation of the cells. Any screening technique known in the art can be used to screen for PAMP agonists or antagonists. The present invention contemplates screens for small molecule ligands or ligand analogs and mimics, as well as screens for natural ligands
5 that bind to and agonize or antagonize the activity of PAMP *in vivo*. For example, natural products libraries can be screened using assays of the invention for molecules that agonize or antagonize PAMP activity.

Another approach uses recombinant bacteriophage to produce large libraries. Using the "phage method" (Scott and Smith, Science 249:386-390, 1990; Cwirla, *et al.*, Proc. Natl. Acad. Sci., 87:6378-6382, 1990; Devlin *et al.*, Science, 49:404-406, 1990), very large libraries can be constructed (10^6 - 10^8 chemical entities). A second approach uses primarily chemical methods, of which the Geysen method (Geysen *et al.*, Molecular Immunology 23:709-715, 1986; Geysen *et al.* J. Immunologic Method 102:259-274, 1987; and the
15 method of Fodor *et al.* (Science 251:767-773, 1991) are examples. Furka *et al.* (14th Int. Congress of Biochemistry, Volume 5, Abstract FR:013, 1988; Furka, Int. J. Peptide Protein Res. 37:487-493, 1991), Houghton (U.S. Patent No. 4,631,211, issued December 1986) and Rutter *et al.* (U.S. Patent No. 5,010,175, issued April 23, 1991) describe methods to produce a mixture of
20 peptides that can be tested as agonists or antagonists.

In another aspect, synthetic libraries (Needels *et al.*, Proc. Natl. Acad. Sci. USA 90:10700-4, 1993; Ohlmeyer *et al.*, Proc. Natl. Acad. Sci. USA 90:10922-10926, 1993; Lam *et al.*, International Patent Publ. No. WO 92/00252; Kocis *et al.*, International Patent Publ. No. WO 9428028) and the
25 like can be used to screen for PAMP ligands according to the present invention.

Knowledge of the primary sequence of the protein, and the similarity of that sequence with proteins of known function, can provide an initial clue as to the inhibitors or antagonists of the protein. As noted above,
30 identification and screening of antagonists is further facilitated by determining structural features of the protein, e.g., using X-ray crystallography, neutron diffraction, nuclear magnetic resonance spectrometry, and other techniques for structure determination. These techniques provide for the rational design or identification of agonists and antagonists.

35 The PAMP protein sequence (including parts thereof) can be used to deduce the structural organization and topology of PAMP through the

use of a variety of techniques including CD spectroscopy, nuclear magnetic resonance (NMR) spectroscopy, X-ray crystallography, and molecular modeling. Sequences for PAMP or PAMP mutants can also be used to identify proteins which interact with PAMP either in concert with PS1 and PS2, or independently, using a variety of methods including co-immunoprecipitation, yeast two hybrid interaction trap assays, yeast three hybrid interaction trap assays, chemical cross-linking and co-precipitation studies, etc. These and other methods are described more fully in co-pending and commonly assigned U.S. Application Serial No. 08/888,077, filed July 3, 1997, and 09/227,725, filed January 8, 1999, both of which are incorporated herein by reference. Identification of these interacting partners will then lead to their use to further delineate the biochemical pathways leading to the above-mentioned diseases.

Finally, the structural analysis of PAMP, when combined with structural analysis of PS1 and PS2, and other proteins which interact with PAMP or PAMP mutants, will identify the structural domains that mediate interactions between these molecules and which also confer biological activity on PAMP (or PAMP and these other molecules). These structural domains, and other functional domains, which can modulate the activity of these structural domains, can all be modified through a variety of means, including but not limited to site-directed mutagenesis, in order to either augment or reduce the biological activity. The structure and topology of these domains can all be used as a basis for the rational design of pharmaceuticals (small molecule conventional drugs or novel carbohydrate, lipid, DNA/RNA or protein-based high molecular weight biological compounds) to modulate (increase or decrease) the activity of PAMP and/or the PAMP PS1/PS2 complex, and/or the activity of the PAMP/other protein complexes. For example, using structural prediction calculations, possibly in conjunction with spectroscopic data like nuclear magnetic resonance, circular dichroism, and other physical-chemical structural data, or crystallographic data, or both, one can generate molecular models for the structure of PAMP. These models, in turn, are important for rational drug design. Drug candidates generated using a rational drug design program can then be applied for the treatment and/or prevention of the above-mentioned diseases, and can be administered through a variety of means including: as conventional small molecules through enteral or parenteral routes; via inclusion in liposome vehicles;

5 Lentivirus, or herpes simplex virus-based vectors) which allow targeted
expression of appropriately modified gene products in selected cell types. It
should be noted that the recombinant proteins described above may be the
wild-type PAMP, a genetically-modified PAMP, a wild-type PS1/PS2, a
genetically-modified PS1/PS2, or a specially-designed protein or peptide
10 which is designed to interact with either the functional domains of PAMP (or
the PAMP/PS1/PS2/other protein complex) or to interact with the domains
which modulate the activity of the functional domains of PAMP.

PAMP *In Vitro* and *In Vivo* Models

The PAMP nucleotide sequence can be used to make cell-free systems, transfected cell lines, and animal models (invertebrate or vertebrate) of the neurodegenerative and other diseases outlined above. These animal and cell models may involve over-expression of all or part of PAMP or PAMP mutants, e.g., as mini-gene cDNA transgene constructs under the regulation of suitable promoter elements carried in vectors such as cos-Tet for transgenic mice and pcDNA (Invitrogen, California) in transfected cell lines. Animal and cellular models can also be generated by via homologous recombination mediated targeting of the endogenous gene to create artificially mutant sequences (knock-in gene targeting); or loss of function mutations (knock-out gene targeting); by translocation of P-elements; and by chemical mutagenesis. Animal, cellular and cell-free model systems can be used for a variety of purposes including the discovery of diagnostics and therapeutics for this disease.

Included within the scope of this invention is a mammal in which two or more genes have been knocked out or knocked in, or both. Such mammals can be generated by repeating the procedures set forth herein for generating each knockout construct, or by breeding to mammals, each with a single gene knocked out, to each other, and screening for those with the double knockout genotype.

Regulated knockout animals can be prepared using various systems, such as the tet-repressor system (see US Patent No. 5,654,168) or the Cre-Lox system (see US Patents No. 4,959,317 and No. 5,801,030).

Transgenic mammals can be prepared for evaluating the molecular mechanisms of PAMP, and particularly human PAMP/PS1 or PAMP/PS2 function. Such mammals provide excellent models for screening or testing drug candidates. It is possible to evaluate compounds or diseases on "knockout" animals, e.g., to identify a compound that can compensate for a defect in PAMP activity. Alternatively, PAMP (or mutant PAMP), alone or in combination with β APP, PS1, and/or PS2, (double or triple transgenics) "knock-in" mammals can be prepared for evaluating the molecular biology of this system in greater detail than is possible with human subjects. Both technologies permit manipulation of single units of genetic information in their natural position in a cell genome and to examine the results of that manipulation in the background of a terminally differentiated organism. These animals can be evaluated for levels of mRNA or protein expression, processing of β APP, or development of a condition indicative of inappropriate gene expression, e.g., *Notch* phenotype or another phenotype as set forth above, or neurodegeneration, including cognitive deficits, learning or memory deficits, or neuromuscular deficits.

Various transgenic animal systems have been developed. Mice, rats, hamsters, and other rodents are popular, particularly for drug testing, because large numbers of transgenic animals can be bred economically and rapidly. Larger animals, including sheep, goats, pigs, and cows, have been made transgenic as well. Transgenic *D.melanogaster* and *C.elegans* can also be made and, using known genetic methods, may offer the ability to identify upstream and downstream modifiers of a PAMP phenotype. Transgenic animals can also be prepared by introducing the transgene on a vector; such animals, which are not modified in the germ line and are only transiently transgenic, naturally cannot pass along the genetic information to their progeny.

In another series of embodiments, transgenic animals are created in which (i) a human PAMP, or a mutant human PAMP, is stably inserted into the genome of the transgenic animal; and/or (ii) the endogenous PAMP genes are inactivated and replaced with their human counterparts. See, e.g., Coffman, Semin. Nephrol. 17:404, 1997; Esther et al., Lab. Invest.

74:953, 1996; Murakami *et al.*, Blood Press. Suppl. 2:36, 1996. Such animals can be treated with candidate compounds and monitored for the effects of such drugs on PAMP cavity.

5

PAMP Gene Therapy

As discussed above, abnormalities in PAMP expression and/or interactions with PS1/PS2/ β APP are associated with severe neurological deficits. Thus, the present invention provides for treatment of such deficits either with a drug discovered using a screening assay or transgenic animal model, or both, as set forth above, or by replacing a defective *PAMP* gene with a functional gene by gene therapy.

A gene encoding PAMP, a PAMP mutant, or alternatively a negative regulator of PAMP such as an antisense nucleic acid, intracellular antibody (intrabody), or dominant negative PAMP (which may be truncated), can be introduced *in vivo*, *ex vivo*, or *in vitro* using a viral or a non-viral vector, e.g., as discussed above. Expression in targeted tissues can be effected by targeting the transgenic vector to specific cells, such as with a viral vector or a receptor ligand, or by using a tissue-specific promoter, or both. Targeted gene delivery is described in International Patent Publication WO 95/28494, published October 1995.

Preferably, for *in vivo* administration, an appropriate immunosuppressive treatment is employed in conjunction with the viral vector, e.g., adenovirus vector, to avoid immuno-deactivation of the viral vector and transfected cells. For example, immunosuppressive cytokines, such as interleukin 12 (IL-12), interferon- γ (IFN γ), or anti-CD4 antibody, can be administered to block humoral or cellular immune responses to the viral vectors (see, e.g., Wilson, Nature Medicine, 1995). In that regard, it is advantageous to employ a viral vector that is engineered to express a minimal number of antigens.

Herpes virus vectors. Because herpes virus is trophic for cells of the nervous system (neural cells), it is an attractive vector for delivery of function *PAMP* genes. Various defective (non-replicating, and thus non-infectious) herpes virus vectors have been described, such as a defective herpes virus 1 (HSV1) vector (Kaplitt *et al.*, Molec. Cell. Neurosci. 2:320-330, 1991; International Patent Publication No. WO 94/21807, published

September 29, 1994; International Patent Publication No. WO 92/05263, published April 2, 1994).

Adenovirus vectors. Adenoviruses are eukaryotic DNA viruses that can be modified to efficiently deliver a nucleic acid of the invention to a variety of cell types *in vivo*, and has been used extensively in gene therapy protocols, including for targeting genes to neural cells. Various serotypes of adenovirus exist. Of these serotypes, preference is given to using type 2 or type 5 human adenoviruses (Ad 2 or Ad 5) or adenoviruses of animal origin (see WO94/26914). Those adenoviruses of animal origin which can be used within the scope of the present invention include adenoviruses of canine, bovine, murine (example: Mav1, Beard *et al.*, Virology 75 (1990) 81), ovine, porcine, avian, and simian (example: SAV) origin. Preferably, the adenovirus of animal origin is a canine adenovirus, more preferably a CAV2 adenovirus (e.g., Manhattan or A26/61 strain (ATCC VR-800), for example). Various replication defective adenovirus and minimum adenovirus vectors have been described for gene therapy (WO94/26914, WO95/02697, WO94/28938, WO94/28152, WO94/12649, WO95/02697 WO96/22378). The replication defective recombinant adenoviruses according to the invention can be prepared by any technique known to the person skilled in the art (Levrero *et al.*, Gene 101:195 1991; EP 185 573; Graham, EMBO J. 3:2917, 1984; Graham *et al.*, J. Gen. Virol. 36:59 1977). Recombinant adenoviruses are recovered and purified using standard molecular biological techniques, which are well known to one of ordinary skill in the art.

Adeno-associated viruses. The adeno-associated viruses (AAV) are DNA viruses of relatively small size which can integrate, in a stable and site-specific manner, into the genome of the cells which they infect. They are able to infect a wide spectrum of cells without inducing any effects on cellular growth, morphology or differentiation, and they do not appear to be involved in human pathologies. The AAV genome has been cloned, sequenced and characterized. The use of vectors derived from the AAVs for transferring genes *in vitro* and *in vivo* has been described (see WO 91/18088; WO 93/09239; US 4,797,368, US 5,139,941, EP 488 528). The replication defective recombinant AAVs according to the invention can be prepared by co-transfecting a plasmid containing the nucleic acid sequence of interest flanked by two AAV inverted terminal repeat (ITR) regions, and a plasmid carrying the AAV encapsidation genes (rep and cap genes), into a cell line

which is infected with a human helper virus (for example an adenovirus). The AAV recombinants which are produced are then purified by standard techniques.

Retrovirus vectors. In another embodiment the gene can be introduced in a retroviral vector, e.g., as described in Anderson *et al.*; U.S. Patent No. 5,399,346; Mann *et al.*, 1983, Cell 33:153; Temin *et al.*, U.S. Patent No. 4,650,764; Temin *et al.*, U.S. Patent No. 4,980,289; Markowitz *et al.*, 1988, J. Virol. 62:1120; Temin *et al.*, U.S. Patent No. 5,124,263; EP 453242, EP178220; Bernstein *et al.* Genet. Eng. 7 (1985) 235; McCormick; BioTechnology 3 (1985) 689; International Patent Publication No. WO 95/07358, published March 16, 1995, by Dougherty *et al.*; and Kuo *et al.*, 1993, Blood 82:845. The retroviruses are integrating viruses which infect dividing cells. The retrovirus genome includes two LTRs, an encapsidation sequence and three coding regions (*gag*, *pol* and *env*). In recombinant retroviral vectors, the *gag*, *pol* and *env* genes are generally deleted, in whole or in part, and replaced with a heterologous nucleic acid sequence of interest. These vectors can be constructed from different types of retrovirus, such as MoMuLV ("murine Moloney leukemia virus"), MEV ("murine Moloney sarcoma virus"), HaSV ("Harvey sarcoma virus"); SNV ("spleen necrosis virus"); RSV ("Rous sarcoma virus") and Friend virus. Suitable packaging cell lines have been described in the prior art, in particular the cell line PA317 (US 4,861,719); the PsiCRIP cell line (WO 90/02806) and the GP+envAm-12 cell line (WO 89/07150). In addition, the recombinant retroviral vectors can contain modifications within the LTRs for suppressing transcriptional activity as well as extensive encapsidation sequences which may include a part of the *gag* gene (Bender *et al.*, J. Virol. 61:1639, 1987). Recombinant retroviral vectors are purified by standard techniques known to those having ordinary skill in the art.

Retrovirus vectors can also be introduced by recombinant DNA viruses, which permits one cycle of retroviral replication and amplifies transfection efficiency (see WO 95/22617, WO 95/26411, WO 96/39036, WO 97/19182).

Lentivirus vectors. In another embodiment, lentiviral vectors are can be used as agents for the direct delivery and sustained expression of a transgene in several tissue types, including brain, retina, muscle, liver and blood. The vectors can efficiently transduce dividing and non-dividing cells in

these tissues, and maintain long-term expression of the gene of interest. For a review, see, Naldini, Curr. Opin. Biotechnol., 9:457-63, 1998; see also Zufferey, *et al.*, J. Virol., 72:9873-80, 1998). Lentiviral packaging cell lines are available and known generally in the art. They facilitate the production of high-titer lentivirus vectors for gene therapy. An example is a tetracycline-inducible VSV-G pseudotyped lentivirus packaging cell line which can generate virus particles at titers greater than 10⁶ IU/ml for at least 3 to 4 days (Kafri, *et al.*, J. Virol., 73: 576-584, 1999). The vector produced by the inducible cell line can be concentrated as needed for efficiently transducing nondividing cells *in vitro* and *in vivo*.

Non-viral vectors. A vector can be introduced *in vivo* in a non-viral vector, e.g., by lipofection, with other transfection facilitating agents (peptides, polymers, etc.), or as naked DNA. Synthetic cationic lipids can be used to prepare liposomes for *in vivo* transfection, with targeting in some instances (Felgner, *et al.*, Proc. Natl. Acad. Sci. U.S.A. 84:7413-7417, 1987; Felgner and Ringold, Science 337:387-388, 1989; see Mackey, *et al.*, Proc. Natl. Acad. Sci. U.S.A. 85:8027-8031, 1988; Ulmer *et al.*, Science 259:1745-1748, 1993). Useful lipid compounds and compositions for transfer of nucleic acids are described in International Patent Publications WO95/18863 and WO96/17823, and in U.S. Patent No. 5,459,127. Other molecules are also useful for facilitating transfection of a nucleic acid *in vivo*, such as a cationic oligopeptide (e.g., International Patent Publication WO95/21931), peptides derived from DNA binding proteins (e.g., International Patent Publication WO96/25508), or a cationic polymer (e.g., International Patent Publication WO95/21931). Recently, a relatively low voltage, high efficiency *in vivo* DNA transfer technique, termed electrotransfer, has been described (Mir *et al.*, C.P. Acad. Sci., 321:893, 1998; WO 99/01157; WO 99/01158; WO 99/01175). DNA vectors for gene therapy can be introduced into the desired host cells by methods known in the art, e.g., electroporation, microinjection, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun (ballistic transfection), or use of a DNA vector transporter (see, e.g., Wu *et al.*, J. Biol. Chem. 267:963-967, 1992; Wu and Wu, J. Biol. Chem. 263:14621-14624, 1988; Hartmut *et al.*, Canadian Patent Application No. 2,012,311, filed March 15, 1990; Williams *et al.*, Proc. Natl. Acad. Sci. USA 88:2726-2730, 1991). Receptor-mediated DNA delivery approaches can also be used (Curiel *et al.*, Hum. Gene Ther. 3:147-154, 1992; Wu and Wu, J. Biol. Chem. 262:4429-

4432, 1987). US Patent Nos. 5,580,859 and 5,589,466 disclose delivery of exogenous DNA sequences, free of transfection facilitating agents, in a mammal.

5

EXAMPLES

The present invention will be further understood by reference to the following examples, which are provided as exemplary of the invention and not by way of limitation.

10 **EXAMPLE 1: A novel PAMP that mediates β APP processing and Notch/Glp1 signal transduction**

This example shows that both PS1 and PS2 interact with a novel Type I transmembrane protein, PAMP, and that this novel protein also interacts with α - and β -secretase derived fragments of β APP. We also show
15 that abolition of functional expression of the *C. elegans* homologue of the protein leads to a developmental phenotype (anterior pharynx 2 -*aph2*) which is thought to be due to inhibition of the *glp/Notch* signaling pathway. This novel protein is therefore positioned to mediate both the gain of function and loss of function phenotypes associated with presenilin missense mutations
20 and presenilin knockouts, respectively.

Materials and Methods

Antibodies against PS1, PS2 and β APP. An antibody, termed 1142, directed against PS1, was raised to a peptide segment corresponding
25 to residues 30-45 of PS1 (Levesque *et al.*, J Neurochem 1998: 72:999-1008; Yu *et al.*, Biol Chem 1998; 273:16470-16475). The peptide was synthesized by solid-phase techniques and purified by reverse phase high pressure liquid chromatography (HPLC). Peptide antigens were linked to keyhole limpet hemocyanin (KLH) and used, in combination with complete Freud's adjuvant,
30 to inoculate New Zealand White rabbits. Antisera from three rabbits was pooled, ammonium precipitated and the antibody was purified with Sulfo-link (Pierce) agarose-peptide affinity columns. Other antibodies used include antibody 369, a polyclonal rabbit-anti-human antibody directed against the C-terminus of human β APP (Buxbaum *et al.*, Proc. Natl. Acad. Sci. USA 1990;
35 87: 6003-6007); antibody 14 (Ab14), a rabbit polyclonal antibody raised against residues 1-25 of human PS1 (Seeger *et al.*, Proc. Natl. Acad. Sci.

1997; 94: 5090-5094); antibody α -PS1-CTF, a polyclonal rabbit antibody directed against the PS1 loop; and antibody DT2, a monoclonal antibody raised to a GST-fusion protein containing the PS2 N-terminal sequence from residues 1-87.

- 5 **Preparation of presenilin associated components.** To identify membrane associated components of the presenilin complex, an immunoaffinity procedure was used to extract PS1 and tightly associated membrane proteins from semi-purified intracellular membrane fractions. Human embryonic kidney cells (HEK) 293 (ATCC) with a stable over-
10 expression of moderate level wild type human PS1, were grown to confluence, washed twice with ice-cold phosphate-buffered saline, and then homogenized with Buffer A (0.25 M sucrose, 20 mM HEPES pH 7.2, 2 mM EGTA, 2 mM EDTA, 1 mM DTT, and a protease inhibitor cocktail containing 5 μ g/ml each of Leupeptin, Antipain, pepstatin A, Chymostatin, E64, Aprotinin,
15 and 60 μ g/ml 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF)). The cell homogenates were centrifuged 1000 \times g for 10 minutes to remove cell debris. The supernatant was then centrifuged 10,000 \times g for 60 minutes. The resulting membrane pellet was resuspended in Buffer B (20 mM HEPES pH 7.2, 1 M KCl, 2 mM EGTA, 2 mM EDTA, 1 mM DTT, and protease inhibitor cocktail as
20 above) and incubated for 45 minutes with agitation at 4°C. Cell membranes were collected again by centrifugation at 107,000 \times g for 60 minutes. The cell membranes were then lysed on ice for 60 minutes with Buffer C (1% Digitonin, 20 mM HEPES pH 7.2, 100 mM KCl, 2 mM EGTA, 2 mM EDTA, 1 mM DTT, and protease inhibitors cocktail). After spinning 10,000 \times g for 15
25 minutes, the protein extract was adjusted with Buffer C to contain 5 mg/ml protein. A total of 0.5 g of protein was obtained.

- Isolation.** The extracted proteins were then subjected to fractionation with 10-40% glycerol gradient containing 0.5% Digitonin as described (Yu G, *et al.*, J Biol Chem 1998; 273: 16470-16475). After being
30 verified by Western blotting with anti-PS1 antibodies, the peak fractions containing PS1 were pooled and incubated overnight with Protein A/G agarose coupled with either antibody 1142 or a control IgG purified from preimmune rabbit serum. The Protein A/G agarose beads were washed three times with Buffer D (1% Digitonin, 20 mM HEPES pH 7.2, 100 mM KCl, protease inhibitors cocktail), and three times with Buffer E (0.5% Digitonin,
35 0.5% CHAPS, 20 mM HEPES pH 7.2, 100 mM KCl, 10 mM CaCl₂, 5 mM

MgCl₂, and the protease inhibitor cocktail as above). Isolated protein complexes were eluted from the beads with 0.1M Glycine-HCl, pH 3.0, and then neutralized with 1M Tris. Proteins were then separated by Tris-Glycine SDS-PAGE gels and stained with silver stain and Coomassie Blue stain. The staining of the immuno-purified proteins displayed two intense bands in addition to those of the presenilin holoprotein and its fragments.

Sequence analysis. Individual protein bands were cut out and analyzed with solid-phase extraction capillary electrophoresis mass spectrometry/mass spectrometry (SPE-CE-MS/MS). Briefly, protein bands were first digested in-gel with trypsin; the digested proteins were extracted and dried in a speed vacuum down to concentrate the peptides; and the peptides thereafter separated with micro LC and analyzed by on-line tandem mass spectrometry (Figeys et al., Anal Chem 1999; 71: 2279-2287). Nucleotide and amino acid sequence homology searches were conducted using the BLAST algorithm, and motif analyses performed using the program BLOCKS.

General transfection and analysis methods. Based on the human PAMP sequence, public databases (e.g., GenBank; www.ncbi.nlm.nih.gov) were searched for homologous ESTs (SEQ ID NOs: 3-10), which were collected into a few contigs. These contigs all turned out to be correct, but did not cover full-length mouse and *D. melanogaster* cDNAs.

Full length murine (SEQ ID NO: 15), human (SEQ ID NO: 13) and *D. melanogaster* (SEQ ID NO: 17) PAMP cDNAs were obtained using oligonucleotides designed from partial cDNA/EST sequences in public databases to screen appropriate cDNA libraries, for 5'RACE, and/or for RT-PCR experiments. A PAMP expression construct was generated by inserting human PAMP cDNA in-frame with the V5 epitope of pcDNA6 (Invitrogen) at the C-terminus of PAMP. HEK293 cells with a stable expression of PS1/PS2 and β APP_{sw} were transiently transfected with either V5-tagged PAMP or empty plasmid (mock transfection control). Duplicate experiments were performed by: (1) transient transfection of V5-PAMP and β APP₆₉₅ (or empty vector plus β APP₆₉₅ as a mock transfection control) into murine embryonic fibroblasts stably infected with human PS1 expressed from a retroviral vector construct (Clontech, CA); or (2) transient transfection of V5-PAMP (or an empty plasmid) into HEK293 cell lines with a stable expression of the C-terminal 99 amino acids of β APP with a preceding artificial signal peptide

(spC100-APP) together with either wild type PS1, PS1-L392V, or PS1-D385A. Cells were lysed with a Digitonin lysis buffer or with 1% NP40, and the protein extracts were subjected to gradient fraction, immunoprecipitation or direct Western blotting as described (Yu G, *et al.*, J Biol Chem 1998; 273: 16470-16475). PS1 was immunodetected or immunoprecipitated with antibodies 14 or α -PS1-CTF; and PS2 was immunodetected or immunoprecipitated with antibody DT2. FL- β APP and its C-terminal α - and β -secretase derivatives were detected using antibody 369.

10

Results

Isolation of PAMP. Immunoprecipitation of PS1 protein complexes, followed by SDS-PAGE with Coomassie Blue and silver staining, yielded two intense bands in addition to presenilin holoprotein. These bands were characterized by mass spectroscopy analysis. Mass spectroscopy analysis revealed several *armadillo* repeat containing peptides, (previously known to functionally interact with presenilins (Yu G, *et al.*, J Biol Chem 1998; 273: 16470-16475.; Zhou J, *et al.*, NeuroReport (Fast Track) 1997; 8: 2085-2090; Nishimura M, *et al.*, Nature Med 1999; 5: 164-169), and a novel peptide (PAMP) which had a sequence identified to that predicted for an anonymous, partial cDNA (Genbank; Accession No. D87442). The cDNA sequence predicted an open reading frame of 709 amino acids (SEQ ID NO: 14), which contains a putative N-terminal signal peptide, a long N-terminal hydrophilic domain with sequence motifs for glycosylation, N-myristoylation and phosphorylation, a ~20 residue hydrophobic putative transmembrane domain, and a short hydrophilic C-terminus of 20 residues (Figure 1A and 1B).

Orthologous PAMP proteins. The PAMP amino acid sequence had no significant homology to other proteins within available databases, except for a hypothetical *C.elegans* protein (www.ncbi.nih.gov; Accession No. Q23316) ($p = 2 \times 10^{-28}$; identity = 22%; similarity = 39%) (SEQ ID NO: 12) ascertained from a genomic DNA sequence (Figure 1A and 1B). In addition to strong primary amino acid sequence conservation, this *C.elegans* protein has a very similar topology to human PAMP, suggesting that it is the nematode orthologue of human PAMP.

In the absence of functional clues arising from homologues to other known proteins, the predicted amino acid sequences of the murine

(SEQ ID NO: 16) and *D.melanogaster* (SEQ ID NO: 18) orthologues of PAMP were cloned and examined. The four orthologous PAMP proteins had a similar topology and significant sequence conservation near residues 306-360, 419-458, and 625-662 of human PAMP (SEQ ID NO: 14) (Figure 1A and 1B). Motif analysis of these conserved domains revealed a weak similarity (strength = 1046) between residues 625 – 641 (ARLARALSPAFELSQWS; SEQ ID NO: 19) of mouse and human PAMP to cyclic nucleotide binding domains. While the putative transmembrane domain sequences were not highly conserved, all four orthologues contained a conserved serine residue within this hydrophobic domain. Finally, there were four conserved cysteine residues in the – terminal hydrophilic domain (Cys₁₉₅, Cys₂₁₃, Cys₂₃₀, and Cys₂₄₈ in human PAMP) which had a periodicity of 16-17 residues in the N-terminus, and may form a functional domain (e.g., a metal binding domain or disulfide bridges for stabilizing the tertiary structure of PAMP/PAMP complexes).

Interaction of PAMP with presenilin 1. To confirm the authenticity of the PAMP:PS1 interaction, HEK293 cells were transiently transfected with PAMP cDNA (SEQ ID NO: 13) tagged at the 3'-end with a V5-epitope encoded from the pcDNA6 vector. The conditioned media were collected 20 hr after transient transfection with PAMP (or with empty vector), and the A β ₄₀ and A β ₄₂ levels were measured by ELISA (Zhang L, *et al.*, J Biol Chem 1999; 274: 8966-8972.). In Western blots of lysates of these cells, the use of anti-V5 (Invitrogen, CA) and enhanced chemiluminescence (Amersham) detected a V5- immunoreactive band of ~110 kDa which was reduced to ~80 kDa following Endo H digestion (equivalent to the size predicted from the PAMP amino acid sequence), confirming the predicted glycosylation of PAMP. In addition, a series of about 7-10 kDa fragments were observed, which are predicted to contain the TM domain and short C-terminus of PAMP plus the 3 kDa V5- epitope. These C-terminal derivatives may be authentic cleavage products of full-length PAMP, or, alternatively, a proteolytic artifact arising from the attachment of the V5-epitope to the C-terminus of PAMP.

Reciprocal immunoprecipitation studies in cells expressing combinations of transfected V5-tagged-PAMP, transfected wild type or mutant PS1, transfected wild type PS2, or endogenous presenilins, confirmed the PS1:PAMP interaction, and showed a similar interaction between PAMP and

PS2. In contrast, immunoprecipitation of other ER-resident proteins (e.g., calnexin) failed to show any evidence of an interaction between these proteins and PAMP. Glycerol velocity gradient analysis of the native conformation of PAMP revealed that PAMP was co-eluted into the same high molecular weight fractions as PS1 and PS2, indicating that it is an authentic component of the high molecular weight presenilin protein complexes. These biochemical data were supported by immunocytochemical studies, which showed that transfected PAMP and endogenous PS1 strongly co-localized in the ER and Golgi in MDCK canine kidney/epithelial cells (ATCC). Similar studies with PS2 confirmed that PAMP also tightly associates with both endogenous PS2 in human brain and with transfected PS2 in HEK293 cells.

The PAMP gene. Chromosomal locations and genetic map positions of the murine and human PAMPS were obtained from public genetic and transcriptional maps (www.ncbi.nlm.nih.gov). The gene encoding PAMP is located on human chromosome 1 near the genetic markers D1S1595 and D1S2844. The 5'- end of the PAMP gene is embedded in the 5'- end of the coatmer gene encoded on the opposite strand. The human PAMP gene is close to a cluster of markers which have yielded positive, but sub-significant evidence for linkage to or association with Alzheimer Disease in two independent genome wide surveys (Kehoe P, *et al.* Hum Mol Genet 1999; 8: 237-245). The murine PAMP maps within a 700 Kb interval of murine chromosome 1 which contains the gene defect associated with *Looptail* phenotype in mice (Underhill DA, *et al.*, Genomics 1999; 55: 185-193). Mice heterozygous for *Looptail* show developmental defects in dorsal axial structures including notochord, brain, spinal cord, and somites (Greene ND, *et al.*, Mech Dev 1998; 73: 59-72.), which are reminiscent of those observed in PS1^{-/-} mice (Shen J, *et al.*, Cell 1997; 89: 629-639; Wong PC, *et al.*, Nature 1997; 387:288-292). These observations suggest that the presenilin: PAMP complex may be involved in both β APP and Notch processing.

C. elegans homolog of PAMP. The *C. elegans* homolog of PAMP corresponds to the *aph-2* gene. Mutations in *aph-2* have been identified in a screen for mutants with phenotypes identical to embryonic mutant phenotypes caused by loss of *glp-1* activity, i.e., lack of an anterior pharynx, e.g. cDNA clone. The EST corresponding to *aph-2*, (cDNA clone yk477b8, kindly provided by Y. Kohara, National Institute of Genetics, Japan) was sequenced and the coding region (SEQ ID NO: 11) found to match

exactly the Genefinder prediction made by the *C. elegans* sequencing consortium (Genbank; Accession No. Z75714). Double stranded RNA interference (RNAi) confirmed the mutant phenotype of *aph-2*. Sense and antisense RNA were transcribed *in vitro* from PCR product amplified from the phage yk477b8. After annealing equal quantities of sense and antisense products, the dsRNA product made was injected into L4 stage wild-type worms. The chosen line of worms, designated lin-12(n302) (Greenwald and Seydoux, Nature 1990; 346:197-199; Greenwald, *et al.*, Cell 1983; 34; 435-444) was obtained from the Caenorhabditis Genetics Center. Injected animals were transferred to fresh plates daily and the progeny scored at least 36 hours after injection for the embryonic lethal phenotype and 4-5 days after injection for the egg-laying phenotypes. Animals injected with dsRNA from yk477b8 template produced eggs that lacked an anterior pharynx. These results support the notion that *aph-2*/PAMP contributes to cell interactions mediated by *glp-1/Notch* in the embryo.

Functional role for the PAMP:presenilin complexes in β APP processing. To examine a functional role for the PAMP:presenilin complexes in β APP processing, the interactions between PAMP, PS1, and β APP, and its derivatives were investigated. The cell lines used were transiently transfected with V5-tagged PAMP, and stably expressed wild type β APP₆₉₅ in addition to one of wild type PS1, wild type PS2, PS1-L392V mutant, or PS1-D385A mutant. The PS1-L392V mutation is a pathogenic mutation associated with familial AD (Sherrington R, *et al.*, Nature 1995; 375:754-760) and with increased secretion of A β ₄₂ (Scheuner D, *et al.* Nature Med 1996; 2: 864-870, Citron M, *et al.* Nature Med 1997; 3: 67-72). The PS1-D385A mutation is a loss of function mutation associated with inhibition of PS1 endoproteolysis and a decrease in γ -secretase activity (Wolfe MS, *et al.*, Nature 1999; 398: 513-517). The conditioned media were collected 20 hr after transient transfection with PAMP (or with empty vector), and the A β ₄₀ and A β ₄₂ levels were measured by ELISA (Zhang L, *et al.*, J Biol Chem 1999; 274: 8966-8972). Analysis of Western blots from these co-immunoprecipitation experiments revealed that PAMP holoprotein (and C-terminally tagged proteolytic fragments of PAMP) interacted in equivalent degrees with wild type PS1, wild type PS2, PS1-L392V mutant, and PS1-D385A mutant proteins. In addition, PAMP holoprotein and the C-terminal proteolytic fragments of PAMP also co-immunoprecipitated with the C-terminal proteolytic fragments of β APP

but not β APP holoprotein in lysates of cells expressing either β APP holoprotein or just the C-terminal 99 amino acids of β APP. Significantly, compared to cells expressing equivalent quantities of wild type PS1, cell lines expressing pathogenic mutations of PS1 showed increased amounts of C-terminal β APP fragments co-immunoprecipitating with PAMP. Conversely, cell lines expressing the loss-of-function PS1-D385A mutation showed greatly reduced amounts of C-terminal β APP derivatives co-immunoprecipitating with PAMP despite the presence of very large amounts of C-terminal β APP derivatives in these cells.

These results were confirmed in HEK293 cells over-expressing either β APP_{Swedish} or the SpC99- β APP cDNA. The latter encodes the C-terminal 99 residues of β APP (corresponding to the products of β -secretase cleavage) plus the β APP signal peptide. The interaction of PAMP appears much stronger with C99- β APP than that with C83- β APP. However, C83- β APP is much less abundant in these cells (Fig. 6b, middle panel, lanes 1-4). In fact, PAMP does interact with both C99- and C83- β APP stubs (see Fig. 6c, lane 9 and Fig. 8d). Cumulatively, these results indicate that PAMP likely interacts with the C-terminal derivatives of β APP which are the immediate precursors of A β and p3. However, of greater interest, the genotype of the co-expressed PS1 molecule dynamically influenced the interaction between PAMP and C99-/C83- β APP stubs. Thus, more C-terminal β APP fragments co-immunoprecipitated with PAMP in cells expressing the FAD-associated PS1-L392V mutation compared to cells expressing wild type PS1 (and equivalent quantities of PAMP and C99- β APP). Conversely, much less C-terminal β APP derivatives co-immunoprecipitated with PAMP in cell lines expressing the loss-of-function PS1-D385A mutation (despite the presence of very large amounts of C-terminal β APP derivatives in these cells). These effects are more easily seen in cells over-expressing the C99- β APP construct. However, similar but less pronounced differences were also observed in cells over-expressing full-length β APP_{Swedish}. More importantly, the PS1-sequence-related differences in the interaction of PAMP with C-terminal β APP derivatives were most evident within 24 hours of transient transfection of PAMP. By 72 hours, the PS1-sequence-related differences were largely abolished. This dynamic change in the interaction of PAMP with C99/C83- β APP was not due to changes in the levels of PS1, C-terminal β APP derivatives or PAMP. One interpretation of these results is that the

presenilins may be dynamically involved in regulating or loading PAMP with the substrates of γ -secretase.

Presenilin binding domains of PAMP. In transiently transfected cells (in which the 7-10 kDa C-terminal of PAMP can be detected),
5 anti-PS1 immunoprecipitation products contain both full length PAMP and the
~7-10 kDa C-terminal PAMP fragments. Similarly, in these cells,
immunoprecipitation with antibodies to the C-terminus of β APP (Ab369) also
gives C-terminal PAMP epitopes. The TM domain of PAMP is not highly
conserved in evolution. These results suggest that the C99-/C83- β APP and
10 PS1/PS2-binding domain(s) of PAMP are in the TM domain or C-terminus.

Discussion

The above results indicate that PAMP is a component of the PS1 and PS2 intracellular complexes. The observations that PAMP also
15 binds to the C-terminal fragment of β APP (arising from α - and β -secretase
cleavage of full length β APP), that the degree of binding of these fragments to
PAMP is modulated by mutations in PS1, and that the direction of this
modulation is congruent with the effects of each mutant of A β production (*i.e.*,
the pathogenic L392V mutation increases binding to PAMP and increases
20 A β_{42} production whereas the D385A mutation has the opposite effects)
strongly argues that PAMP is part of a functional complex involved in
processing of C-terminal β APP derivatives. Similarly, the observation that
inhibition of PAMP expression in *C. elegans* leads to a phenotype similar to
that of *glp/Notch* loss of function, argues that PAMP, like PS1 and PS2, is
25 also a functional component of the pathways involved in processing of *Notch*.
This conclusion is strengthened by the fact that the murine PAMP gene maps
within a 700 kb interval on murine chromosome 1 which carries the *Looptail*
mutant, and is thus likely to be the site of the *Looptail* mutation. *Looptail* has
a number of phenotypic similarities to those of *Notch* and PS1 knockouts in
30 mice. Because *Looptail* is a model of human spinal cord malformations
including spina bifida, PAMP biology may also provide some useful insights
into this neurological developmental defect as well.

At the current time the exact role of PAMP in the presenilin-
complex-mediated processing of β APP and *Notch*-like molecules is not fully
35 defined. Inspection of the primary amino acid sequence of PAMP does not
reveal very strong homologies to known proteases. However, the

recombinant expression systems of the invention permit evaluation of three-dimensional structure of PAMP; it is possible that PAMP itself has a protease activity. However, it is currently more plausible that PAMP plays another role in β APP and *Notch* processing. Thus, PAMP may be involved in the function of PS1 and PS2 complexes by binding substrates for γ -secretase. The efficacy of this binding is clearly modulated by PS1 mutations in a direction which is commensurate with the effect of these mutations on γ -secretase activity. Alternatively, PAMP may have a regulatory role on the activity of the presenilin complexes. This is consistent with the observation that residues 625-641 of human and murine PAMP contain a motif similar to cyclic nucleotide binding domains of several other unrelated proteins.

Regardless of its precise role, it is clear that PAMP and PS1 both play important roles in γ -secretase mediated processing of β APP. Hence, knowledge of PAMP and its biology will now serve as a target for efforts to manipulate the function of the presenilin complexes in patients with Alzheimer Disease and related disorders, patients with malignancies (in which the presenilins have been implicated by virtue of a role in programmed cell death), and in disorders of development especially of the spinal cord and brain (in view of the known effects of PS1 knockout and the strong likelihood that PAMP is the site of *Looptail* mutations in mice). In particular, knowledge of the domains of PAMP involved in binding presenilins and β APP derivatives (which currently appears to be located within the C-terminal transmembrane and hydrophilic domains of PAMP) and the identification of putative ligands interacting with the conserved domains at the hydrophilic N-terminus of PAMP will considerably expedite this goal.

It has been found that the strength of the interaction between PAMP and the C-terminal fragments of β APP (which is the precursor A β) is determined by the genotype at PS1. Thus, clinical mutations in PS1 which cause Alzheimer's Disease and an increase in the production of A β_{42} are associated with increased binding of the C-terminal fragments of β APP to PAMP. Conversely, loss of function mutations in PS1 (Asp385Ala) which inhibit γ -secretase cleavage of C-terminal fragments of β APP, are associated with abolition of the interaction between PAMP and the C-terminal fragments of β APP.

Finally, the apparent C-terminal proteolytic derivatives of PAMP could either be authentic, or simply artefacts due to the V-5 tag. If they are

authentic, this observation raises the possibility that PAMP may undergo post-translational processing events which are potentially similar to those of β APP and/or *Notch*. Three observations support our discovery of PAMP. First, in contrast to β APP and *Notch*, which are not major constituents of the high molecular weight presenilin complexes, and which can only be inconsistently shown to be directly associated with PS1/PS2, PAMP is a major stoichiometric component of the presenilin complexes. Second, PAMP selectively interacts only with C-terminal derivatives of β APP which are substrates for γ -secretase cleavage, and this interaction is modulated by PS1 mutations in a way which reflects the functional consequences of these PS1 mutations. Third, inhibition of PAMP expression in *C. elegans* leads to a disease phenotype likely to be in the *glp/Notch* signaling pathway.

EXAMPLE 2: PAMP mutants useful for studies on Alzheimer's Disease

Site-directed mutagenesis was used to generate the following artificial mutations in PAMP:

	Cys:	PAMP _{C230A} in the 4 conserved cystine motif
	DYIGS:	PAMP _{D336A/Y337A} in the central conserved region
20	D369L:	PAMP _{Δ312-369} in the central conserved region
	D340X:	PAMP _{Δ312-340} in the central conserved region
	YDT:	PAMP _{D458A} in the putative 'aspartyl protease' DTA site
	SPAF:	PAMP _{P633A/F635A} in the SPAF motif
	TM:	PAMP _{S683A} in the TM domain
25	C3D:	PAMP _{Δ630-668} in the conserved region adjacent to the TM domain

To further examine the role of PAMP in β APP processing, we inserted PAMP cDNAs harboring the above mutations, as well as normal/wild type PAMP (PAMP_{wt}) cDNA and the cDNA for an unrelated protein (LacZ), in frame into pcDNA6 vectors. A series of HEK293 cell lines stably expressing endogenous PS1, β APP_{Swedish} and either wild type PAMP or PAMP constructs in which various conserved domains had been mutated or deleted, were then created by transfection. PAMP expressing cells were selected with lastidicin to generate stable cell lines. Conditioned media from these cell lines were collected after 6-24 hours and A β ₄₀ and A β ₄₂ were measured by ELISA.

In the PAMP_{D336A/Y337A} mutant, both A β ₄₀ and A β ₄₂ levels were increased, and there was also a 68% increase in A β ₄₂/A β ₄₀ ratio which is very similar to that observed in clinical mutations in APP, PS1, and PS2, associated with early onset Alzheimer Disease. The A β ₄₂/A β ₄₀ ratio was also
5 increased in one cell line expressing the PAMP_{C230A} mutant.

In contrast, both the total A β ₄₂ and A β ₄₀ levels and the A β ₄₂/A β ₄₀ ratio were massively reduced (to only 18% of the control) in the PAMP _{Δ 312-369} mutant. A similar but less profound reduction of both the total A β ₄₂ and A β ₄₀ levels and the A β ₄₂/A β ₄₀ ratio was observed in the conditioned medium from
10 the PAMP _{Δ 312-340} cell lines.

There is no apparent difference in A β ₄₂ or A β ₄₀ levels, or in the A β ₄₂/A β ₄₀ ratio, when the PAMP_{wt}, PAMP_{D458A}, PAMP _{Δ 630-668}, PAMP_{P633A/F635A}, and PAMP_{S683A} cells were compared to control lines (expressing LacZ, or empty vector).

15 Thus, certain PAMP mutants cause biochemical changes similar to those induced by mutations in the β APP, PS1, and PS2 genes which give rise to Alzheimer's Disease. These artificial PAMP mutations can therefore be used to generate cellular and other model systems to design treatments and preventions for Alzheimer's Disease related disorders. These mutations also
20 show that PAMP is involved in the pathogenesis of AD, and may provide information for the design of specific molecular diagnostics or therapeutics.

When compared to mock-transfected or LacZ transfected cells, overexpression of wild type PAMP, and overexpression of most PAMP mutation- or deletion-constructs had no significant effect on A β secretion.
25 However, missense mutation of the conserved DYIGS motif to AAIGS (residues 336-340 of human PAMP) caused a significant increase in A β ₄₂ secretion, a smaller increase in A β ₄₀ secretion, and an increase in the A β ₄₂/A β ₄₀ ratio ($p < 0.001$; Table 2). This increase in A β ₄₂ production was equivalent to that of FAD-related missense mutations in PS1. Conversely,
30 deletion of the DYIGS domain in two independent constructs (PAMP _{Δ 312-369} and PAMP _{Δ 312-340}) caused a significant reduction in both A β ₄₂ and A β ₄₀ secretion which was more profound in PAMP _{Δ 312-369} cells than in PAMP _{Δ 312-340} cells (Table 2). The magnitude of the reduction in A β secretion in PAMP _{Δ 312-369} cells was equivalent to that observed with the PS1-D385A loss-of-function
35 mutation. Somewhat unexpectedly, and in contrast to PS1^{-/-} and PS1-D385A cells, the reduction in A β secretion in NCT _{Δ 312-369} and NCT _{Δ 312-340} cells was not

accompanied by the expected accumulation of C99- and C83- β APP stubs. Since there was no consistent change in the levels of soluble β APP (β APP_s) in the conditioned medium of any of the PAMP mutant cells, the most probable explanation for this result is that C99- and C83- β APP stubs which do
5 not enter the PAMP:presenilin complex for γ -secretase cleavage to A β may be degraded by other pathways.

The effects of PAMP mutations on A β secretion were not due to trivial explanations such as differences in the levels of PAMP, β APP holoprotein, or PS1/PS2. None of these mutations caused any consistent,
10 detectable change in the amount of APP_s in conditioned medium or in the amount of C99/C83- β APP that could be co-immunoprecipitated with PAMP. However, both the PAMP $_{\Delta 312-369}$ mutant and the PAMP $_{\Delta 312-340}$ deletion mutant significantly reduced the amount of PS1 which could be co-immunoprecipitated with PAMP. Interestingly, the reduction in efficiency of
15 binding to PS1 was proportional to the reduction in A β secretion induced by each deletion mutant. Multiple mechanisms underlying the effect of mutations in the first conserved domain can explain these results. This domain contains no obvious functional motifs (e.g., for glycosylation etc.), nor does it have significant sequence homology to other known proteins. Consequently, the
20 three functionally active PAMP mutations either affect a presenilin-binding domain in PAMP, or affect a specific regulatory domain of PAMP which modulates both direct binding of PAMP to PS1 and the subsequent γ -secretase-mediated cleavage of PAMP-bound C99- and C83- β APP stubs.

Table 2

Transfection	Normalized A β ₄₂	Normalized A β ₄₀	A β ₄₂ /A β ₄₀ Ratio
Mock (LacZ/empty vector)	1.0	1.0	1.0
Wild type nicastrin	1.03 \pm 0.09	1.05 \pm 0.07	0.99 \pm 0.07
D336A/Y337A	3.09 \pm 0.59 (p < 0.001)	1.61 \pm 0.19 (p = 0.001)	1.81 \pm 0.15 (p < 0.001)
Nicastrin Δ ₃₁₂₋₃₆₉	0.05 \pm 0.04 (p < 0.001)	0.31 \pm 0.06 (p < 0.001)	0.09 \pm 0.05 (p < 0.001)
Nicastrin Δ ₃₁₂₋₃₄₀	0.33 \pm 0.04 (p = 0.002)	0.55 \pm 0.04 (p = 0.001)	0.59 \pm 0.06 (p = 0.003)

5 The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

10 It is further to be understood that values are approximate, and are provided for description.

Patents, patent applications, and publications are cited throughout this application, the disclosures of which are incorporated herein by reference in their entireties.

WE CLAIM:

1. An isolated presenilin associated membrane protein (PAMP), or a functional fragment thereof.
5
2. The PAMP of claim 1, which is human PAMP (SEQ ID NO: 14).
3. The PAMP of claim 1, which is mouse PAMP (SEQ ID NO: 16), *D. Melanogaster* (SEQ ID NO: 18) or *C. elegans* PAMP (SEQ ID NO: 12).
10
4. The PAMP of claim 1, which is a mutant PAMP.
5. The mutant PAMP of claim 4 wherein the mutation results in biochemical changes similar to those induced by mutations in presenilin-1, presenilin-2, or β -amyloid precursor protein associated with familial
15 Alzheimer's Disease.
6. The mutant PAMP of claim 5, wherein the mutation is to an amino acid residue selected from the group consisting of D336, Y337, C230, and both D336 and Y337.
20
7. An isolated nucleic acid encoding the PAMP of claim 1.
8. The nucleic acid of claim 7, which is human (SEQ ID NO: 13).
25
9. The nucleic acid of claim 7, which is mouse (SEQ ID NO: 15), *D. Melanogaster* (SEQ ID NO: 17) or *C. elegans* (SEQ ID NO: 11).
10. A vector comprising the nucleic acid of claim 7 operatively
30 associated with an expression control sequence.
11. A cell transfected with the vector of claim 10.
12. A method for producing PAMP, which method comprises
35 culturing the cell of claim 11 under conditions that permit expression of PAMP.

13. An isolated nucleic acid encoding the mutant PAMP of claim 4.
14. The nucleic acid of claim 13, wherein the mutation results in a change to an amino acid residue selected from the group consisting of D336, Y337, C230, and both D336 and Y337.
15. A vector comprising the nucleic acid of claim 13 operatively associated with an expression control sequence.
16. A cell transfected with the vector of claim 15.
17. A method for producing mutant PAMP, which method comprises culturing the cell of claim 16 under conditions that permit expression of the mutant PAMP.
18. A transgenic animal, comprising a transgene encoding presenilin associated membrane protein (PAMP) which is expressed in neural cells such that the animal detectably expresses *PAMP* mRNA.
19. The transgenic animal of claim 18, which detectably expresses PAMP protein.
20. The transgenic animal of claim 19, which processes β -amyloid precursor protein to produce amyloid- β peptide.
21. The transgenic animal of claim 18, which is a mouse.
22. The transgenic animal of claim 18, wherein PAMP is human PAMP (SEQ ID NO: 14).
23. The transgenic animal of claim 18, wherein said PAMP is a mutant PAMP.
24. The transgenic animal of claim 18, further comprising a second transgene encoding a human presenilin-1, human presenilin-2 or human β -amyloid precursor protein, wherein the human presenilin-1, human presenilin-

2, or human β -amyloid precursor protein is expressed at a level that permits its detection.

5 25. An animal containing a nucleic acid that expresses an endogenous presenilin associated membrane protein (PAMP) at a higher or lower level relative to expression level in a wild-type animal.

10 26. The animal of claim 25, prepared by homologous recombination-mediated targeting of an endogenous PAMP gene.

27. The animal of claim 25, prepared by translocation of P-elements.

15 28. The animal of claim 25, prepared by chemical mutagenesis.

29. An isolated cell containing a nucleic acid that expresses a mutant presenilin associated membrane protein (PAMP).

20 30. The cell of claim 25, wherein the mutation results in biochemical changes similar to those induced by mutations in presenilin-1, presenilin-2 or β -amyloid precursor protein associated with familial Alzheimer's Disease.

25 31. A reconstituted system for measuring presenilin associated membrane protein (PAMP) activity, comprising PAMP or a functional fragment thereof, and a PAMP substrate.

32. The reconstituted system of claim 31, which is a whole cell.

30 33. The reconstituted system of claim 31, wherein said whole cell contains a first nucleic acid that expresses said PAMP and a second nucleic acid that expresses said substrate.

35 34. The reconstituted system of claim 31, wherein said substrate is selected from the group consisting of presenilin-1 protein, presenilin-2 protein and β -amyloid precursor protein.

35. A complex between a presenilin associated membrane protein (PAMP) and an agent which provides a detectable conformational change in said PAMP upon interaction with a substance being analyzed for activity against a neurodegenerative disease.
- 5 36. The complex of claim 35, further comprising presenilin 1 protein, presenilin 2 protein, β -amyloid precursor protein, or a combination thereof.
37. A method for detecting a mutation in presenilin associated
10 membrane protein (PAMP) associated with disease or a related neurological disorder, which method comprises detecting a variation in a sequence of a gene encoding PAMP obtained from an individual diagnosed with or suspected of having a neurodegenerative disorder.
- 15 38. A method for diagnosing individuals predisposed to or having a neurodegenerative disorder, which method comprises detecting a mutation in a gene encoding PAMP obtained from an individual.
39. The method according to claim 38, wherein detection of the
20 mutation comprises measuring a level of transcriptional activity of the gene.
40. The method according to claim 38, wherein detection of the mutation comprises measuring PAMP activity.
- 25 41. The method of claim 40, wherein said PAMP activity comprises PAMP expression level or activity of a product of a PAMP modified substrate.
42. A method for identifying a compound that modulates PAMP
30 activity, which method comprises detecting modulation of PAMP expression in a transgenic animal that expresses PAMP, wherein the animal is contacted with the compound.
43. A method for identifying a compound that modulates PAMP
35 activity, which method comprises detecting a change in PAMP activity in the reconstituted system of claim 31 contacted with a test compound.

44. A method for identifying a compound that modulates PAMP activity, which method comprises detecting a conformational or functional change in PAMP in the complex of claim 35 contacted with a test compound.
- 5 45. The method of claim 44, wherein the compound is a protein that interacts with PAMP.

1/2

Hum: 1 MATAGGSGADPGSRGLLRLSFCVLLAGLCRGNVERKIYIPLNKTAPCVRLLNATHQI 60
 Mou MAT GSG DPGSRGLL LLSF V+LAGLC GNSVERKIYIPLNKTAPCVRLLNATHQI
 Dros: 1 A + +G K+Y P+ A C R LN THQ
 C.ele L +++AG+C G S + + + + C R N TH+

Hum 61 GCQSSISGDTGVIHVVEKEEDLQWVLTGDPNPPYMLLESKHFTDRIMEKLGKRTSRIAG 120
 Mou GCQSSISGDTGVIHVVEKEEDL+WVLTGDPNPPYMLLE K FTRD+MEKLG TSRIAG
 Dros GC S+ SG GV+H++ E DL+++L+ P+PPY ++ FTR+ + +LK +
 C.eleg GCQ++ + G+I ++K+ED + W + Y LL RD + +LK + ++G

Hum: 121 LAVSLTKSPASGFSVQCPNDGFGVYSNGPEFAHCRIOQNSLGNLAYEDFSFPI 180
 Mou LAV+L KP+ S FSPSVQCPNDGFG YSNSYGPEFAH ++ WN LG GLAYED SFPI
 Dros + + + + + FS + CPN G+ S S + + + + WN G GL +EDF FPI
 C.eleg + +S + + + S +CPN Y E+ E + NS G+GL D+ +

Hum: 181 FLEDENETKVIKQCYQDHNLSQNSAPTFFPLCAMOLFSSHMAVISTATCMRRSSIQSTF 240
 Mou FLEDE+ETKVIKQCYQDHNLS QNSAP+FFPLCAMOLFSSHMAVISTATCMRRSSIQSTF
 Dros: + + D ++ +++C+QD N + LCA+++ S M A ++T CMRR++ +
 C.eleg +++ + ++I++CY N + + +P C M A ++ C RR + F

Hum: 241 SINPEIVCDPLSDYNVWSMLKPFINTTGTCLKPDDRVVVAATRLDSRFF+WNVAPGAESAV 299
 Mous SINPEIVCDPLSDYNVWSMLKPFINT+ L+PD RVVVAATRLDSRFF WNVAPG ESAP
 Dros ++ C+PL NV P +T T+ +++ ++ RLD+ + F V GA ++
 C.eleg +N + +C + N+++ PI T+ T + + ++ R+DS ++ G S +

Hum: 300 ASFVTQAAAAEALQAPDVTTILPRNVMFVFFQGETFDYIGSSRMVYDMEKGFVQLENV 359
 Mou ASFVTQAAAAEAL KAPDVTTIL.RNVMFVFFQGETFDYIGSSRMVYDME KGFV+LEN+
 Dros F A LQ P + NV+V F GE+DYIGS R VIDMEK +Fp+ +N+
 C.eleg S ++ LAAA ++/QKA + + RNV F FF GE+ DYIGS Y ME GKFP++ +

Figure 1A

2/2

Hum: 360 DSFVELGQVALRTSLELWMTDPVSQKNESVRNQVEDLLATLEKSGAGVPAVILRRPNS 419
 Mou DSFVELGQVALRTSL+LWMTDP+SQKNESV+NQVEDLLATLEKSGAGVP V+LRR QS
 Dros D +++G + ++++L + ++ Q+ + L KS G I + S
 C.eleg D +E+ Q+ + + ++H D ++ + + Q + ++ +E+ G A L +P+ S

Hum 420 QPLPSSLQRLRARNISGVVLADHSGAFHNKYQSYDTEININVSYPEWLSPEEDLNF 479
 Mou Q PPSSLQRLRARNISGVVLADHSG+FNH+YYQSYDTEININVSYPEW S EEDLNF
 Dros LPP+S Q FLR N + ++L + NKYY S YD A+N++ +Y L
 C.eleg +PP+S F +A ++ V+LA + + + S+ D EW E +

Hum 480 VTD TAKALADVATVLRALYELAGTNFSDTVQADPQTVTLLYGLIKANNS/FQSILR 539
 Mous VTD TAKALA+VATVL RALYELAGTNFS ++QADPQTVTLLYGL++ANNSWFQSIL+
 Dros V D DV+++ ALY+ G ++ T A+P LY FL A+ F++
 C.eleg + + V+T + A + G + D + +T ++ LI +N WF

Hum : 540 QDLRSYLGQPLQHYIAVSSPTNTTVVQYALANLTGTVNLTREOCQDPSKVPSENKDL 599
 Mous DLSYL D PLQHYIAVSSPTNTTVVQYAL NLTRCQDPSKVP+E+KDL
 Dros S L + P YI+V + + Y L L+ ++ R+ C D
 C.eleg Q L SY G YI++ SPT ++ +AL + T+ + + C + + +

Hum: 600 YEYSWVQGPLHSNETDRLPRCVRSTARLARALSPAFELSQWSSTEYSTWESRWKDIRAR 659
 Mous YEYSWVQGP +SN T+RLP+CVRST RLARALSPAFELSQWSSTEYSTW ESRWKDI+AR
 Dros PLH + + C +T + ALSPAF + WSS YSTWES W AR
 C.eleg Y Y+W P N + C+S +SPA + + +T YSTW ES +

Hum: 660 IFLIASKELELITLVGFGILIFSLIVTYCINAKADVLFAPREPAGVSY 709
 Mous IFLIASKELE ITL VGF L+FSLIVTYCINAKADVLF+APREPAGVSY
 Dros IFL S ++ 'L+VG +LI S + Y I++++VLF
 C.eleg ++L+ E + + +I +L+ + + ++ FI EP A

Figure 1B

1/19

SEQUENCE LISTING

<110> The Governing Council of The University of Toronto

<120> A novel presenilin associated membrane
protein and uses thereof

<130> 9267-61/PAR

<160> 19

<170> FastSEQ for Windows Version 3.0

<210> 1

<400> 1

000

<210> 2

<400> 2

000

<210> 3

<211> 422

<212> DNA

<213> mouse

<400> 3

```
cccagcggag aggcaagatg gctacgacta ggggcggctc tgggcctgac ccaggaagtc
60
ggggtcttct tcttctgtct ttttccgtgg tactggcagg attgtgtggg ggaaactcag
120
tggagaggaa aatctacatt cccttaaata aaacagctcc ttgtgtccgc ctgctcaacg
180
ccactcatca gattggctgc cagtcttcaa ttagtgggga tacaggggtt atccatgtag
240
tggagaaaga agaagactga agtgggtggt gacgatggcc ccaacccctt tacatggtct
300
gctggaggga agtcttcaca gagatgtaat ggagaagctg aggacaacag tagatcctgg
360
tcttgccgtg attagcagcc actcacttaa gtttctctag tgtgagtgcc aatgatgggt
420
tt
422
```

<210> 4

<211> 473

<212> DNA

<213> unknown

<220>

<223> EST from unknown organism

<400> 4

2/19

tggagaggaa aatctacatt cccttaaata aaacagctcc ttgtgtccgc ctgctcaacg
60
ccactcatca gattggctgc cagtcttcaa ttagtgggga tacaggggtt atccatgtag
120
tggagaaaga agaagacctg aagtgggtgt tgaccgatgg cccaacccc ccttacatgg
180
ttctgttgga gggcaagctc ttcaccagag atgtaatgga gaagctgaag ggaacaaaca
240
gtagaatcgc tgggtcttgc gtgactctag ccaagcccaa ctcaacttca agcttctctc
300
ctagtgtgca gtgcccacat gatgggtttg gtaattactc caactcctac gggccagagt
360
ttgctcactg gaagaaaaca ctgtggaatg aactcggcaa aggcttggct tatgaagacc
420
ttagtttccc caatcttctt cctggagatg aggaccgaaa caaggtcatc aag
473

<210> 5

<220>

<223> null

<400> 5

000

<210> 6

<211> 463

<212> DNA

<213> unknown

<220>

<223> EST from unknown organism

<400> 6

gggctcgaaa catctctggc gtggtcctgg ctgaccactc tggctccttc cacaatcggt
60
attaccagag catcttatgac acggttgaga acattaatgt gacctatcct gagtggcaga
120
gccatgaaga ggacctcaac tttgtgacag aacttgccaa ggcaactggcg aatgtggcca
180
cagtgtctggc gcgtgcactg tatgagcttg caggaggaac caacttcagc agctccatcc
240
aggctgatcc ccagacagtt acacgtctgc tctatgggtt cctgggttaga gctaacaact
300
catgggtttca gtgatcctg aaacatgacc taagggtcta tttggatgac aggcctcttc
360
aacactacat cgccgtctcc agccctacca acacgactta cgttgtgcag tacgccttgg
420
caaacctgac tgggcaaggc gaccaacctc acccgagagc agt
463

<210> 7

<211> 481

<212> DNA

<213> unknown

<220>

<223> EST from unknown organism

3/19

<400> 7

gaggacctca actttgtgac agacactgcc aaggcactgg cgaatgtggc cacagtgctg
60
gcgcgtgcac tgtatgagct tgcaggagga accaacttca gcagctccat ccaggctgat
120
ccccagacag ttacacgtct gctctatggg ttccctggta gagctaacaa ctcatggttt
180
cagtcgatct tgaacatga cctaagggtcc tatttggatg acaggcctct tcaacactac
240
atcgccgtct ccagccctac caacacgact tacgttgtgc agtacgcctt ggcaaacctg
300
actggcaagg cgaccaacct cacccgagag cagtgccagg atccaagtaa agtcccaaat
360
gagagcaagg atttatatga atactcgtgg gtacaaggcc cttggaattc caacaggaca
420
gagaggctcc cacagtgtgt gcgctcacag tgcgactggc aagggttgt cctgccttt
480
g
481

<210> 8

<211> 398

<212> DNA

<213> unknown

<220>

<223> EST from unknown organism

<400> 8

agagctaaca actcatgggt tcagtcgatc ttgaaacatg acctaaggcc tatttggatg
60
acaggcctct tcaacactac atcgccgtct ccagccctac caacacgact tacgttgtgc
120
agtacgcctt ggaaacctga ctggcaaggc gaccaacctc acccgagagc agtgccagga
180
tccaagtaaa gtcccaaatg agagcaagga tttatatgaa tactcgtggg tacaaggccc
240
ttggaattcc aacaggacag agaggctccc acagtgtgtg cgctccacag tgcgactggc
300
cagggccttg tcccctgect ttgaactgag tcagtggagc tccacagaat actctacgtg
360
ggcggagagc cgctggaaag acatccaagc tcggatat
398

<210> 9

<211> 172

<212> DNA

<213> unknown

<220>

<223> EST from unknown organism

<400> 9

tgtgcgctcc acagtgcgac tggccagggc gttgtcacct gcctttgaac tgagtcagtg
60
gagctccaca gaatactcta cgtgggcgga gagcgcgtgg aaagacatcc cagctcggat
120

4/19

attcctaatt gccagcaaag agcttgagtt catcacgctg atcgtgggct tc
172

<210> 10
<211> 425
<212> DNA
<213> unknown

<220>
<223> EST from unknown organism

<400> 10
tttttttttt ttttttgtat tgcataatth taatgaaact tgctatttat atacttacaa
60
aaaaaaaaaa aaaggaaaaa accccaacaa aaatagataa ttatagttha ataataaaaa
120
gtacaaactga gcaactgtggg ctggagggtgg gatacccact taacagcgtg cccacactaa
180
catgccatct gcacacctgg agaaaggaca gtgggaaaga gacactggct cagccaggga
240
atccatttct tccctaaggg ttcagggtag ttgaatgcag atgcacaatc tttcacacc
300
tcttcctggg gcagcagggt gctgaatatg ggggaggggt gtcgggtgac agtggagtca
360
gagggcagta cagggcagga tggaggaca gaaggtatcc cgagaaaggg cagaggaggg
420
tggtg
425

<210> 11
<211> 4560
<212> DNA
<213> C. Elegans

<400> 11
attaagaacg aatgagtcga tagaagcact gaaaaatgaa gaaatggcta gttatagtat
60
taattatcgc tggaatacga tgcgacggat tttcggtatca agttttccga actctgttca
120
ttggagaagg aaatgcgtgc tatagaactt ttaataaaaac gcacgaattc ggttgtcaag
180
gtaaaaattg aatgatttca aataattaca tataaaaaaa tattgcaactg ttttttcatt
240
attttcattg aaaattagtg tcaaaatatg tataaatcaa tatttatctg aaaataactg
300
gaaatataga gaaagtgtc caaaatggcc aaaacgttgt caattgccga agacgatact
360
ctataataaa cggcaattgg caactttcgg gctgtttttc aacactgttc aatttgtcag
420
atgaaaataa ttttattttc agttaactca agtgattttc tatattgtgg cagtgaaaaa
480
aattcatagg ccattttgta gaattgccga aaataactcc acctctgaat tacatgcatt
540
ttcactagaa aatatcattt acatacattt taatttataa atatccagta tttatttatt
600
ttcttaaact cattttcaag aaaaatattt tcagctaata gagaaaaacga gaatggccta
660

6/19

acacgttgat ggagaacgat atcaacagaa taagacacag acagatcgag ttattgatcg
2460
aattgaacga ggtcttcgta gtcattgctt tgatcttgaa aaaccatctg gaagtggaga
2520
taggtgggtg catcgaaaat agtttttttt ttcaagaaca tacagaaaac gaaaagcttt
2580
taaagcattt tctttaaaaa ttaaaacaat ttgagcatat gttaaactaca attccgagtg
2640
tcgttttttcg aaaaaagtct aaaattaaaa aaaagcttat cgctcactat ttttcgaaaa
2700
taagggtattt ttcctttaat aaaggcaaac gaaaaatctt cagccatgga taggtgaatt
2760
atagaaataa ttttcaaaaa ttttctttt tcagagttcc acccgcaagt tggcactcgt
2820
ttgccaaaggc tgatgctcac gttcaatcag ttctccttgc accatatggt aaagaatatg
2880
aatatcaacg agttaattca attttgata aaaatgagtg gacagaagac gaacgagaga
2940
aagcaattca agagattgaa gctgtttcta ctgctattct ggcagcagcc gctgattatg
3000
ttggagttga aactgatgaa gttgttgcaa aagttgataa aaaattggta tgtattcttt
3060
ttttttttaa ttttaaaact ttcagcgaca atttagatgt tttattgttg aatttgaaat
3120
ttgcagtatt tttaaatact taaaacaaaa tccctgatga cgcagcgatt catcgctgta
3180
ttttctaatt gctgaaattg aattccatat atatggaata tttcatatct ttacatataa
3240
acgttttttt ttttcagata accactatat tcgattgtct catcacttcc aatttctggt
3300
tcgactgtga ttttatgcaa aaactcgatg gcggtcgcta ccacaagctg ttttaattcct
3360
acggttttaa tcaaaaatca acatatattt caatggaatc ccatactgca ttccttaccg
3420
tactccattg gttaactatt ttcgcttttg gtagtgacaa agaaacattg aatgtgaaaa
3480
gtgaaaagag ctgctcacat cttggtcaat ttcaagcggg gagtttttat tttaaacgaa
3540
tatcaaataa ttaaaatagt tttccgccag tttcagatgt atacctacac gtggcaaccg
3600
aatccgtaca ccggaattt cagttgtctg aaatctgcaa ttgttaaaaa agtaatggtt
3660
tcgccggctg tagattctca aacaccgaa gaagaaatga acacgagata ttcaacatgg
3720
atggaatcag tttatattat tgaatctgtg aatttatatt tgatggaaga tgcttcattt
3780
gaatatacaa tgattctgat tgcggttatt tctgctttat tatcaatctt tgcagttggt
3840
tagttttttt ttcaaaaaaa aaattacaaa aataaatcac aagctttcga gctttctcgt
3900
attcgaaaat gaaggagttt cgcattaaag aaaactagat tttgaatcag tttttcta
3960
ctttagagaa attatactca catttgatgc ccagaaaagt ttgcgacttt tgagccaaaa
4020
gcacgggtgcc aggtctcgac acgaaaaatt tatattaatt gaaaatatgt ttgcgcattt
4080
aaatgggtact gtattttcga attctcattg ctggcgattt aaaaaaatgc attttttaaa
4140


```
<210> 12
<211> 721
<212> PRT
<213> C. Elegans
```

NSDOCID: <WO 0060069A1 | >

8/19

Phe	Gly	Met	Ile	Pro	Glu	Ile	Ser	Val	Gly	Glu	Val	Ser	Val	Leu	Thr
290						295					300				
Ser	Ile	Ile	Ser	Val	Leu	Ala	Ala	Ala	Arg	Ser	Met	Gly	Thr	Gln	Ile
305					310					315					320
Glu	Lys	Trp	Gln	Lys	Ala	Ser	Asn	Thr	Ser	Asn	Arg	Asn	Val	Phe	Phe
				325					330					335	
Ala	Phe	Phe	Asn	Gly	Glu	Ser	Leu	Asp	Tyr	Ile	Gly	Ser	Gly	Ala	Ala
			340					345					350		
Ala	Tyr	Gln	Met	Glu	Asn	Gly	Lys	Phe	Pro	Gln	Met	Ile	Arg	Ser	Asp
	355					360						365			
Arg	Thr	His	Ile	His	Pro	Ile	Arg	Pro	Asn	Glu	Leu	Asp	Tyr	Ile	Leu
370						375						380			
Glu	Val	Gln	Gln	Ile	Gly	Val	Ala	Lys	Gly	Arg	Lys	Tyr	Tyr	Val	His
385					390					395					400
Val	Asp	Gly	Glu	Arg	Tyr	Gln	Gln	Asn	Lys	Thr	Gln	Thr	Asp	Arg	Val
				405					410					415	
Ile	Asp	Arg	Ile	Glu	Arg	Gly	Leu	Arg	Ser	His	Ala	Phe	Asp	Leu	Glu
			420					425					430		
Lys	Pro	Ser	Gly	Ser	Gly	Asp	Arg	Val	Pro	Pro	Ala	Ser	Trp	His	Ser
	435					440						445			
Phe	Ala	Lys	Ala	Asp	Ala	His	Val	Gln	Ser	Val	Leu	Leu	Ala	Pro	Tyr
450						455					460				
Gly	Lys	Glu	Tyr	Glu	Tyr	Gln	Arg	Val	Asn	Ser	Ile	Leu	Asp	Lys	Asn
465					470					475					480
Glu	Trp	Thr	Glu	Asp	Glu	Arg	Glu	Lys	Ala	Ile	Gln	Glu	Ile	Glu	Ala
				485					490					495	
Val	Ser	Thr	Ala	Ile	Leu	Ala	Ala	Ala	Ala	Asp	Tyr	Val	Gly	Val	Glu
			500					505					510		
Thr	Asp	Glu	Val	Val	Ala	Lys	Val	Asp	Lys	Lys	Leu	Ile	Thr	Thr	Ile
	515						520					525			
Phe	Asp	Cys	Leu	Ile	Thr	Ser	Asn	Phe	Trp	Phe	Asp	Cys	Asp	Phe	Met
530						535					540				
Gln	Lys	Leu	Asp	Gly	Gly	Arg	Tyr	His	Lys	Leu	Phe	Asn	Ser	Tyr	Gly
545					550					555					560
Phe	Asn	Gln	Lys	Ser	Thr	Tyr	Ile	Ser	Met	Glu	Ser	His	Thr	Ala	Phe
				565					570					575	
Pro	Thr	Val	Leu	His	Trp	Leu	Thr	Ile	Phe	Ala	Leu	Gly	Ser	Asp	Lys
			580					585					590		
Glu	Thr	Leu	Asn	Val	Lys	Ser	Glu	Lys	Ser	Cys	Ser	His	Leu	Gly	Gln
		595					600					605			
Phe	Gln	Ala	Met	Tyr	Thr	Tyr	Thr	Trp	Gln	Pro	Asn	Pro	Tyr	Thr	Gly
	610					615					620				
Asn	Phe	Ser	Cys	Leu	Lys	Ser	Ala	Ile	Val	Lys	Lys	Val	Met	Val	Ser
625					630					635					640
Pro	Ala	Val	Asp	Ser	Gln	Thr	Pro	Glu	Glu	Glu	Met	Asn	Thr	Arg	Tyr
				645					650					655	
Ser	Thr	Trp	Met	Glu	Ser	Val	Tyr	Ile	Ile	Glu	Ser	Val	Asn	Leu	Tyr
			660					665					670		
Leu	Met	Glu	Asp	Ala	Ser	Phe	Glu	Tyr	Thr	Met	Ile	Leu	Ile	Ala	Val
	675						680					685			
Ile	Ser	Ala	Leu	Leu	Ser	Ile	Phe	Ala	Val	Gly	Arg	Cys	Ser	Glu	Thr
	690					695					700				
Thr	Phe	Ile	Val	Asp	Glu	Gly	Glu	Pro	Ala	Ala	Glu	Gly	Gly	Glu	Pro
705					710					715					720
Leu															

9/19

<210> 13
<211> 2949
<212> DNA
<213> human

<400> 13

tctgcagaat tcggttgcg cctggaaaca cgaacttccg gtctcttagg ctccgggcca
60
cagagacggt gtcagtggta gcctagagag gccgctaaca gacaggagcc gaacgggggc
120
ttccgctcag cagagaggca agatggctac ggaggggggt ggctctgggg ctgacccggg
180
aagtcgggggt ctccctcgcc ttctgtcttt ctgcgtccta ctacaggtt tgtgcagggg
240
aaactcagtg gagaggaaga tatatatccc cttaaataaa acagctccct gtgttcgcct
300
gctcaacgcc actcatcaga ttggctgccg gtcttcaatt agtgagagaca caggggttat
360
ccacgtagta gagaaagagg aggacctaca gtgggtattg actgatggcc ccaaccccc
420
ttacatggtt ctgctggaga gcaagcattt taccagggat ttaatggaga agctgaaagg
480
gagaaccagc cgaattgctg gtcttgaggt gtccctgacc aagcccagtc ctgcctcagg
540
cttctctcct agtgtacagt gcccaaatga tgggtttggt gtttactcca attcctatgg
600
gccagagttt gctcactgca gagaaataca gtggaattcg ctgggcaatg gtttggtta
660
tgaagacttt agtttcccca tctttcttct tgaagatgaa aatgaaacca aagtcacaa
720
gcagtgttat caagatcaca acctgagtcg gaatggctca gcaccaacct tcccactatg
780
tgccatgcag ctcttttcac acatgcatgc tgtcatcagc actgccacct gcctgctgga
840
cagctccatc caaagcacct tcagcatcaa cccagaaatc gtctgtgacc ccctgtctga
900
ttacaatgtg tggagcatgc taaagcctat aaatacaact gggacattaa agcctgacga
960
caggggtgtg gttgctgccg cccggctgga tagtcgttcc tttttctgga atgtggcccc
1020
aggggctgaa agcgcagtgg ctccctttgt caccagctg gctgctgctg aagctttgca
1080
aaaggcacct gatgtgacca ccctgccccg caatgtcatg tttgtcttct ttcaagggga
1140
aacttttgac tacattggca gctcgaggat ggtctacgat atggagaagg gcaagtttcc
1200
cgtgcagtta gagaatgttg actcatttgt ggagctggga caggtggcct taagaacttc
1260
attagagctt tggatgcaca cagatcctgt ttctcagaaa aatgagtcgt tacggaacca
1320
gggtggaggat ctcttgccca cattggagaa gagtgggtgt ggtgtccctg ctgtcatcct
1380
caggaggcca aatcagtcgc agcctctccc accatcttcc ctgcagcgat ttcttcgagc
1440
tcgaaacatc tctggcgttg ttctggctga ccactctggt gccttcata acaaataa
1500
ccagagtatt tacgacactg ctgagaacat taatgtgagc tatcccgaaat ggctgagccc
1560

10/19

tgaagaggac ctgaactttg taacagacac tgccaaggcc ctggcagatg tggccacggt
 1620
 gctgggacgt gctctgtatg agcttgagg aggaaccaac ttcagcgaca cagttcaggc
 1680
 tgatcccccac acggttaccc gcctgctcta tgggttcctg attaaagcca acaactcatg
 1740
 gttccagtct atcctcaggc aggacctaaag gtctacttg ggtgacgggc ctcttcacaca
 1800
 ttacatcgct gtctccagcc ccaccaacac cacttatgtt gtacagtatg ccttggcaca
 1860
 tttgactggc acagtgggtca acctcaccgc agagcagtgc caggatccaa gtaaagtccc
 1920
 aagtgaaaac aaggatctgt atgagtactc atgggtccag ggccctttgc attctaata
 1980
 gacggaccga ctccccgggt gtgtgcgttc tactgcacga ttagccaggc ccttgtctcc
 2040
 tgcctttgaa ctgagtcagt ggagctctac tgaatactct acatggactg agagccgctg
 2100
 gaaagatatc cgtgcccgga tttttctcat cgccagcaaa gagcttgagt tgatcacctc
 2160
 gacagtgggc ttcggcatcc tcatcttctc cctcatcgtc acctactgca tcaatgccaa
 2220
 agctgatgtc cttttcattg ctccccggga gccaggagct gtgtcatact gagsaggacc
 2280
 scagcttttc ttgccagctc agcagttcac ttcctagagc atctgtccca ctgggacaca
 2340
 accactaatt tgtcactgga acctccctgg gcctgtctca gattgggatt aacataaaaag
 2400
 agtggaaacta tccaaaagag acagggagaa ataaataaat tgctccctt cctccgctcc
 2460
 cctttcccat cacccttcc ccatttctc ttccttctc actcatgcca gatattggga
 2520
 ttacaaatag aagcttcttg ctctgttta actccctagt taccaccct aatttgcct
 2580
 tcaggaccct tctacttttt ccttccctgcc ctgtacctct ctctgtctct caccctcc
 2640
 cctgtacca gccaccttcc tgactgggaa ggacataaaa ggtttaatgt cagggtcaaa
 2700
 ctacattgag cccctgagga caggggcac tctgggctga gcctactgtc tccttccac
 2760
 tgtcctttct ccaggccctc agatggcaca ttaggggtggg cgtgctgagg gtgggtatcc
 2820
 cacctccagc ccacagtgtc cagttgtact ttttattaag ctgtaatatc tatttttgtt
 2880
 tttgtctttt tcttttatcc tttttgtaaa tatatatata atgagtttca ttaaaataga
 2940
 ttatccac
 2949

<210> 14
 <211> 709
 <212> PRT
 <213> human

<400> 14
 Met Ala Thr Ala Gly Gly Gly Ser Gly Ala Asp Pro Gly Ser Arg Gly
 1 5 10 15

11/19

Leu Leu Arg Leu Leu Ser Phe Cys Val Leu Leu Ala Gly Leu Cys Arg
 20 25 30
 Gly Asn Ser Val Glu Arg Lys Ile Tyr Ile Pro Leu Asn Lys Thr Ala
 35 40 45
 Pro Cys Val Arg Leu Leu Asn Ala Thr His Gln Ile Gly Cys Gln Ser
 50 55 60
 Ser Ile Ser Gly Asp Thr Gly Val Ile His Val Val Glu Lys Glu Glu
 65 70 75 80
 Asp Leu Gln Trp Val Leu Thr Asp Gly Pro Asn Pro Pro Tyr Met Val
 85 90 95
 Leu Leu Glu Ser Lys His Phe Thr Arg Asp Leu Met Glu Lys Leu Lys
 100 105 110
 Gly Arg Thr Ser Arg Ile Ala Gly Leu Ala Val Ser Leu Thr Lys Pro
 115 120 125
 Ser Pro Ala Ser Gly Phe Ser Pro Ser Val Gln Cys Pro Asn Asp Gly
 130 135 140
 Phe Gly Val Tyr Ser Asn Ser Tyr Gly Pro Glu Phe Ala His Cys Arg
 145 150 155 160
 Glu Ile Gln Trp Asn Ser Leu Gly Asn Gly Leu Ala Tyr Glu Asp Phe
 165 170 175
 Ser Phe Pro Ile Phe Leu Leu Glu Asp Glu Asn Glu Thr Lys Val Ile
 180 185 190
 Lys Gln Cys Tyr Gln Asp His Asn Leu Ser Gln Asn Gly Ser Ala Pro
 195 200 205
 Thr Phe Pro Leu Cys Ala Met Gln Leu Phe Ser His Met His Ala Val
 210 215 220
 Ile Ser Thr Ala Thr Cys Met Arg Arg Ser Ser Ile Gln Ser Thr Phe
 225 230 235 240
 Ser Ile Asn Pro Glu Ile Val Cys Asp Pro Leu Ser Asp Tyr Asn Val
 245 250 255
 Trp Ser Met Leu Lys Pro Ile Asn Thr Thr Gly Thr Leu Lys Pro Asp
 260 265 270
 Asp Arg Val Val Val Ala Ala Thr Arg Leu Asp Ser Arg Ser Phe Phe
 275 280 285
 Trp Asn Val Ala Pro Gly Ala Glu Ser Ala Val Ala Ser Phe Val Thr
 290 295 300
 Gln Leu Ala Ala Ala Glu Ala Leu Gln Lys Ala Pro Asp Val Thr Thr
 305 310 315 320
 Leu Pro Arg Asn Val Met Phe Val Phe Phe Gln Gly Glu Thr Phe Asp
 325 330 335
 Tyr Ile Gly Ser Ser Arg Met Val Tyr Asp Met Glu Lys Gly Lys Phe
 340 345 350
 Pro Val Gln Leu Glu Asn Val Asp Ser Phe Val Glu Leu Gly Gln Val
 355 360 365
 Ala Leu Arg Thr Ser Leu Glu Leu Trp Met His Thr Asp Pro Val Ser
 370 375 380
 Gln Lys Asn Glu Ser Val Arg Asn Gln Val Glu Asp Leu Leu Ala Thr
 385 390 395 400
 Leu Glu Lys Ser Gly Ala Gly Val Pro Ala Val Ile Leu Arg Arg Pro
 405 410 415
 Asn Gln Ser Gln Pro Leu Pro Pro Ser Ser Leu Gln Arg Phe Leu Arg
 420 425 430
 Ala Arg Asn Ile Ser Gly Val Val Leu Ala Asp His Ser Gly Ala Phe
 435 440 445
 His Asn Lys Tyr Tyr Gln Ser Ile Tyr Asp Thr Ala Glu Asn Ile Asn
 450 455 460
 Val Ser Tyr Pro Glu Trp Leu Ser Pro Glu Glu Asp Leu Asn Phe Val
 465 470 475 480

12/19

Thr Asp Thr Ala Lys Ala Leu Ala Asp Val Ala Thr Val Leu Gly Arg
 485 490 495
 Ala Leu Tyr Glu Leu Ala Gly Gly Thr Asn Phe Ser Asp Thr Val Gln
 500 505 510
 Ala Asp Pro Gln Thr Val Thr Arg Leu Leu Tyr Gly Phe Leu Ile Lys
 515 520 525
 Ala Asn Asn Ser Trp Phe Gln Ser Ile Leu Arg Gln Asp Leu Arg Ser
 530 535 540
 Tyr Leu Gly Asp Gly Pro Leu Gln His Tyr Ile Ala Val Ser Ser Pro
 545 550 555 560
 Thr Asn Thr Thr Tyr Val Val Gln Tyr Ala Leu Ala Asn Leu Thr Gly
 565 570 575
 Thr Val Val Asn Leu Thr Arg Glu Gln Cys Gln Asp Pro Ser Lys Val
 580 585 590
 Pro Ser Glu Asn Lys Asp Leu Tyr Glu Tyr Ser Trp Val Gln Gly Pro
 595 600 605
 Leu His Ser Asn Glu Thr Asp Arg Leu Pro Arg Cys Val Arg Ser Thr
 610 615 620
 Ala Arg Leu Ala Arg Ala Leu Ser Pro Ala Phe Glu Leu Ser Gln Trp
 625 630 635 640
 Ser Ser Thr Glu Tyr Ser Thr Trp Thr Glu Ser Arg Trp Lys Asp Ile
 645 650 655
 Arg Ala Arg Ile Phe Leu Ile Ala Ser Lys Glu Leu Glu Leu Ile Thr
 660 665 670
 Leu Thr Val Gly Phe Gly Ile Leu Ile Phe Ser Leu Ile Val Thr Tyr
 675 680 685
 Cys Ile Asn Ala Lys Ala Asp Val Leu Phe Ile Ala Pro Arg Glu Pro
 690 695 700
 Gly Ala Val Ser Tyr
 705

<210> 15
 <211> 2250
 <212> DNA
 <213> mouse

<400> 15
 cccagcggag aggcacatg gctacgacta gggcgggctc tgggcctgac ccaggaagtc
 60
 ggggtcttct tcttctgtct tttccgtgg tactggcagg attgtgtggg ggaaactcag
 120
 tggagaggaa aatctacatt cccttaaata aaacagctcc ttgtgtccgc ctgctcaacg
 180
 ccactcatca gattggctgc cagtcttcaa ttagtgggga tacagggggt atccacgtag
 240
 tggagaaaga agaagacctg aagtgggtgt tgaccgatgg ccccaacccc cttacatgg
 300
 ttctgctgga gggcaagctc ttcaccagag atgtaatgga gaagctgaag ggaacaacca
 360
 gtagaatcgc tggctctgccc gtgactctag ccaagcccaa ctcaacttca agcttctctc
 420
 ctagtgtgca gtgccccaaat gatgggtttg gtatttactc caactcctac gggccagagt
 480
 ttgctcactg caagaaaaca ctgtggaatg aactgggcaa cggcttggt tatgaagact
 540
 ttagtttccc catctttctt cttgaagatg agaacgaaac caaggtcatc aagcagtgct
 600

14/19

<210> 16
 <211> 708
 <212> PRT
 <213> mouse

<400> 16
 Met Ala Thr Thr Arg Gly Gly Ser Gly Pro Asp Pro Gly Ser Arg Gly
 1 5 10 15
 Leu Leu Leu Leu Ser Phe Ser Val Val Leu Ala Gly Leu Cys Gly Gly
 20 25 30
 Asn Ser Val Glu Arg Lys Ile Tyr Ile Pro Leu Asn Lys Thr Ala Pro
 35 40 45
 Cys Val Arg Leu Leu Asn Ala Thr His Gln Ile Gly Cys Gln Ser Ser
 50 55 60
 Ile Ser Gly Asp Thr Gly Val Ile His Val Val Glu Lys Glu Glu Asp
 65 70 75 80
 Leu Lys Trp Val Leu Thr Asp Gly Pro Asn Pro Pro Tyr Met Val Leu
 85 90 95
 Leu Glu Gly Lys Leu Phe Thr Arg Asp Val Met Glu Lys Leu Lys Gly
 100 105 110
 Thr Thr Ser Arg Ile Ala Gly Leu Ala Val Thr Leu Ala Lys Pro Asn
 115 120 125
 Ser Thr Ser Ser Phe Ser Pro Ser Val Gln Cys Pro Asn Asp Gly Phe
 130 135 140
 Gly Ile Tyr Ser Asn Ser Tyr Gly Pro Glu Phe Ala His Cys Lys Lys
 145 150 155 160
 Thr Leu Trp Asn Glu Leu Gly Asn Gly Leu Ala Tyr Glu Asp Phe Ser
 165 170 175
 Phe Pro Ile Phe Leu Leu Glu Asp Glu Asn Glu Thr Lys Val Ile Lys
 180 185 190
 Gln Cys Tyr Gln Asp His Asn Leu Gly Gln Asn Gly Ser Ala Pro Ser
 195 200 205
 Phe Pro Leu Cys Ala Met Gln Leu Phe Ser His Met His Ala Val Ile
 210 215 220
 Ser Thr Ala Thr Cys Met Arg Arg Ser Phe Ile Gln Ser Thr Phe Ser
 225 230 235 240
 Ile Asn Pro Glu Ile Val Cys Asp Pro Leu Ser Asp Tyr Asn Val Trp
 245 250 255
 Ser Met Leu Lys Pro Ile Asn Thr Ser Val Gly Leu Glu Pro Asp Val
 260 265 270
 Arg Val Val Val Ala Ala Thr Arg Leu Asp Ser Arg Ser Phe Phe Trp
 275 280 285
 Asn Val Ala Pro Gly Ala Glu Ser Ala Val Ala Ser Phe Val Thr Gln
 290 295 300
 Leu Ala Ala Ala Glu Ala Leu His Lys Ala Pro Asp Val Thr Thr Leu
 305 310 315 320
 Ser Arg Asn Val Met Phe Val Phe Phe Gln Gly Glu Thr Phe Asp Tyr
 325 330 335
 Ile Gly Ser Ser Arg Met Val Tyr Asp Met Glu Asn Gly Lys Phe Pro
 340 345 350
 Val Arg Leu Glu Asn Ile Asp Ser Phe Val Glu Leu Gly Gln Val Ala
 355 360 365
 Leu Arg Thr Ser Leu Asp Leu Trp Met His Thr Asp Pro Met Ser Gln
 370 375 380
 Lys Asn Glu Ser Val Lys Asn Gln Val Glu Asp Leu Leu Ala Thr Leu
 385 390 395 400
 Glu Lys Ser Gly Ala Gly Val Pro Glu Val Val Leu Arg Arg Leu Ala
 405 410 415

15/19

Gln Ser Gln Ala Leu Pro Pro Ser Ser Leu Gln Arg Phe Leu Arg Ala
 420 425 430
 Arg Asn Ile Ser Gly Val Val Leu Ala Asp His Ser Gly Ser Phe His
 435 440 445
 Asn Arg Tyr Tyr Gln Ser Ile Tyr Asp Thr Ala Glu Asn Ile Asn Val
 450 455 460
 Thr Tyr Pro Glu Trp Gln Ser Pro Glu Glu Asp Leu Asn Phe Val Thr
 465 470 475 480
 Asp Thr Ala Lys Ala Leu Ala Asn Val Ala Thr Val Leu Ala Arg Ala
 485 490 495
 Leu Tyr Glu Leu Ala Gly Gly Thr Asn Phe Ser Ser Ser Ile Gln Ala
 500 505 510
 Asp Pro Gln Thr Val Thr Arg Leu Leu Tyr Gly Phe Leu Val Lys Ala
 515 520 525
 Asn Asn Ser Trp Phe Gln Ser Ile Leu Lys His Asp Leu Arg Ser Tyr
 530 535 540
 Leu Asp Asp Arg Pro Leu Gln His Tyr Ile Ala Val Ser Ser Pro Thr
 545 550 555 560
 Asn Thr Thr Tyr Val Val Gln Tyr Ala Leu Ala Asn Leu Thr Gly Lys
 565 570 575
 Ala Thr Asn Leu Thr Arg Glu Gln Cys Gln Asp Pro Ser Lys Val Pro
 580 585 590
 Asn Glu Ser Lys Asp Leu Tyr Glu Tyr Ser Trp Val Gln Gly Pro Trp
 595 600 605
 Asn Ser Asn Arg Thr Glu Arg Leu Pro Gln Cys Val Arg Ser Thr Val
 610 615 620
 Arg Leu Ala Arg Ala Leu Ser Pro Ala Phe Glu Leu Ser Gln Trp Ser
 625 630 635 640
 Ser Thr Glu Tyr Ser Thr Trp Ala Glu Ser Arg Trp Lys Asp Ile Gln
 645 650 655
 Ala Arg Ile Phe Leu Ile Ala Ser Lys Lys Leu Glu Phe Ile Thr Leu
 660 665 670
 Ile Val Gly Phe Ser Ile Leu Ile Phe Ser Leu Ile Val Thr Tyr Cys
 675 680 685
 Ile Asn Ala Lys Ala Asp Val Leu Phe Val Ala Pro Arg Glu Pro Gly
 690 695 700
 Ala Val Ser Tyr
 705

<210> 17
 <211> 2942
 <212> DNA
 <213> D. melanogaster

<400> 17
 tctgatatca tcgccactgt gctgggaatt cggcacgagc gcaacactgc aattttctgga
 60
 cgcgatttcg tgggaatctt cgatggaaat gcgtctgaat gcggcttcca tatggctgtt
 120
 aatactgtcg tatggagcaa ctattgctca aggagaaaga acccgcgata agatgtacga
 180
 gcccatctga ggagctagct gtttccgacg gctgaatggc acccatcaga caggctgttc
 240
 ctcaacctac tccggttcg tgggcgtact acatctaata aacgtcgagg ccgacctgga
 300
 attttcttctt agcagccac catctccacc ttacgcccc atgataccac ctcactgtt
 360

cacacgtaac aacctgatgc gcctaaagga agccggacca aagaacattt ctgtggtgct
420
gctgatcaac cgcacgaacc agatgaagca gttctcgac gaactcaact gcccacatca
480
gtacagcggc ctgaacagca ccagtgaagc ctgacgacgc agcaatccag ccaaaaactg
540
gaatccctgg ggcactggac ttctgcacga ggactttccc tttcctatct attacatagg
600
cgatttggat caggtcacca agctagagaa gtgctttcag gactttaaca accataacta
660
cgagacgcac gcgctgcgta gcttgtgcgc cgtcgaggtc aagtccttta tgtccgccc
720
tgtaacacc gaggtctgta tgcgcccgc caacttcac aataatcttg gaggaagcaa
780
gtactgcgat ccgctcgagg gacggaatgt ttgccacct tgtacccccg aaagccagca
840
atcgaaaca actttggaga cagtcacatac gaatgaaaag ttcattatag taacctgtcg
900
cctggacacc accaccatgt tcgatggcgt cggctcttga gccatggact cctcatggg
960
atttgcgttt ttcactcatg tggcgtatct attaaaaca ctacttcgc cgaaagcaa
1020
agacctcat aatgtcctct ttgtgacttt taatggcgaa tcctatgact acattggttc
1080
tcaaagattt gtatacgaca tggagaaact tcaatttcct actgaatcca caggcagcc
1140
tccgattgcc ttgacaata ttgacttcat gctggacatc gggacactgg atgacatatc
1200
gaatattaag ctgcatgcgt taaatggaac gactttggct cagcaaattc tagagcggct
1260
aaataactat gcgaagtcgc cagcgtatgg ctttaacctg aacattcagt ccgagatgag
1320
cgctcactta ccacctacgt cggcgcaatc atttctgca cgtgatccaa acttcaatgc
1380
attgattcta aacgctcgtc caacgaacaa gtattatcat tccacatacg atgacgcgga
1440
taacgtggac ttacactatg cgaacacaag caaggatttc acccagctga cggaagttaa
1500
tgactttaaa agcttgaacc cagattcact gcaaatgaaa gtgcgcaacg tttcctctat
1560
tgtggccatg gccctatatc agacaataac tggaaaggag tacactggca ccaaggtggc
1620
caaccctctg atggcagatg agttccttta ctgtttcctg caatcggcgg actgcccact
1680
ctttaaggcc gcattttatc cgggcagtca gtcaccaat ttgcctccga tgcgctacat
1740
aagcgtcttg ggtggctctc aagagtcgtc gggctatacg tatagattgc tgggctatct
1800
cttgtcacia ctgcagccag acattcacag agataactgc accgacttgc cgctgcacta
1860
tttgcgcgga ttcaacaata tcggagagtg tcgcctcacc acgcagaact acagtcacgc
1920
cctgagtcca gctttcttta ttgatggcta cgattggagt tccggcatgt attccacttg
1980
gactgaatcc acctggtcac agttcagtgc acgcatcttc ctgcgcccgt ccaatgttga
2040
ccaggtcaca actctaagcg ttggcatagt ggtgctgata atatccttct gtttgggtga
2100

17/19

tataatcagc tcacgatcgg aagtcctctt tgaggatttg ccggcaagca atgccgcatt
 2160
 atttggttga tgtcacaact gccacagcga cgaaatcatc gcgttcagca gctcattcca
 2220
 tagattttctg catgcgtaaa ctaaacgtta cttgtaaacc aatcgattaa gaattttctga
 2280
 ttgtgccctt ttagatcgcc gcggccgaca gcctgttaaa tcttcaaaga atatctgattc
 2340
 acgtgccgaa gatgattggg tgctgaatat gatctaaaac aaaaaacaga ctttaacaaag
 2400
 acactaaaat gatattctaa ctgctcttat ttaaaacatt aagcaaacgt ttatttatat
 2460
 gtatttttgt attttaaagt agtaaattag cttctatcaa ctacgttgta tcatatatag
 2520
 acatttaacc aattgcgaca aaattctttc cacttgctcg gccctttttg cattgtacat
 2580
 aggattaacc aaccaattg aacctctgat aatgccaaagg aagagatgtc tgtacaaata
 2640
 ttgacaagaa actgctataa cttataaatc actggaaata tttatacctt ctgcatctat
 2700
 tgcgatactg aacttaatga tctgaaatca ttacttcata gaagacaaat aattattata
 2760
 acgactttaa atttatatag ttaataaat tttgataagg tgtaaagcaa tgcctgttta
 2820
 tctagttagg ttattttcaa ggcaattatt cacagctctc agattccaac gattgatgta
 2880
 gtttaatctc aactctttac caaagaagtc catttggtact agtgtaaaag atattttcaa
 2940
 ta
 2942

<210> 18
 <211> 695
 <212> PRT
 <213> D. melanogaster

<400> 18
 Met Glu Met Arg Leu Asn Ala Ala Ser Ile Trp Leu Leu Ile Leu Ser
 1 5 10 15
 Tyr Gly Ala Thr Ile Ala Gln Gly Glu Arg Thr Arg Asp Lys Met Tyr
 20 25 30
 Glu Pro Ile Gly Gly Ala Ser Cys Phe Arg Arg Leu Asn Gly Thr His
 35 40 45
 Gln Thr Gly Cys Ser Ser Thr Tyr Ser Gly Ser Val Gly Val Leu His
 50 55 60
 Leu Ile Asn Val Glu Ala Asp Leu Glu Phe Leu Leu Ser Ser Pro Pro
 65 70 75 80
 Ser Pro Pro Tyr Ala Pro Met Ile Pro Pro His Leu Phe Thr Arg Asn
 85 90 95
 Asn Leu Met Arg Leu Lys Glu Ala Gly Pro Lys Asn Ile Ser Val Val
 100 105 110
 Leu Leu Ile Asn Arg Thr Asn Gln Met Lys Gln Phe Ser His Glu Leu
 115 120 125
 Asn Cys Pro Asn Gln Tyr Ser Gly Leu Asn Ser Thr Ser Glu Thr Cys
 130 135 140
 Asp Ala Ser Asn Pro Ala Lys Asn Trp Asn Pro Trp Gly Thr Gly Leu
 145 150 155 160

Leu	His	Glu	Asp	Phe	Pro	Phe	Pro	Ile	Tyr	Tyr	Ile	Ala	Asp	Leu	Asp		
				165					170					175			
Gln	Val	Thr	Lys	Leu	Glu	Lys	Cys	Phe	Gln	Asp	Phe	Asn	Asn	His	Asn		
			180					185					190				
Tyr	Glu	Thr	His	Ala	Leu	Arg	Ser	Leu	Cys	Ala	Val	Glu	Val	Lys	Ser		
		195					200					205					
Phe	Met	Ser	Ala	Ala	Val	Asn	Thr	Glu	Val	Cys	Met	Arg	Arg	Thr	Asn		
	210					215					220						
Phe	Ile	Asn	Asn	Leu	Gly	Gly	Ser	Lys	Tyr	Cys	Asp	Pro	Leu	Glu	Gly		
225					230					235				240			
Arg	Asn	Val	Ser	Pro	Pro	Cys	Thr	Pro	Glu	Ser	Gln	Gln	Ser	Glu	Thr		
				245					250					255			
Thr	Leu	Glu	Thr	Val	His	Thr	Asn	Glu	Lys	Phe	Ile	Leu	Val	Thr	Cys		
			260					265					270				
Arg	Leu	Asp	Thr	Thr	Thr	Met	Phe	Asp	Gly	Val	Gly	Leu	Gly	Ala	Met		
		275				280						285					
Asp	Ser	Leu	Met	Gly	Phe	Ala	Val	Phe	Thr	His	Val	Ala	Tyr	Leu	Leu		
	290					295					300						
Lys	Gln	Leu	Leu	Pro	Pro	Gln	Ser	Lys	Asp	Leu	His	Asn	Val	Leu	Phe		
305					310					315				320			
Val	Thr	Phe	Asn	Gly	Glu	Ser	Tyr	Asp	Tyr	Ile	Gly	Ser	Gln	Arg	Phe		
				325					330					335			
Val	Tyr	Asp	Met	Glu	Lys	Leu	Gln	Phe	Pro	Thr	Glu	Ser	Thr	Gly	Thr		
		340						345					350				
Pro	Pro	Ile	Ala	Phe	Asp	Asn	Ile	Asp	Phe	Met	Leu	Asp	Ile	Gly	Thr		
		355				360						365					
Leu	Asp	Asp	Ile	Ser	Asn	Ile	Lys	Leu	His	Ala	Leu	Asn	Gly	Thr	Thr		
	370					375					380						
Leu	Ala	Gln	Gln	Ile	Leu	Glu	Arg	Leu	Asn	Asn	Tyr	Ala	Lys	Ser	Pro		
385					390					395				400			
Arg	Tyr	Gly	Phe	Asn	Leu	Asn	Ile	Gln	Ser	Glu	Met	Ser	Ala	His	Leu		
				405					410					415			
Pro	Pro	Thr	Ser	Ala	Gln	Ser	Phe	Leu	Arg	Arg	Asp	Pro	Asn	Phe	Asn		
			420					425					430				
Ala	Leu	Ile	Leu	Asn	Ala	Arg	Pro	Thr	Asn	Lys	Tyr	Tyr	His	Ser	Thr		
		435				440						445					
Tyr	Asp	Asp	Ala	Asp	Asn	Val	Asp	Phe	Thr	Tyr	Ala	Asn	Thr	Ser	Lys		
	450					455					460						
Asp	Phe	Thr	Gln	Leu	Thr	Glu	Val	Asn	Asp	Phe	Lys	Ser	Leu	Asn	Pro		
465					470					475				480			
Asp	Ser	Leu	Gln	Met	Lys	Val	Arg	Asn	Val	Ser	Ser	Ile	Val	Ala	Met		
				485					490					495			
Ala	Leu	Tyr	Gln	Thr	Ile	Thr	Gly	Lys	Glu	Tyr	Thr	Gly	Thr	Lys	Val		
			500					505					510				
Ala	Asn	Pro	Leu	Met	Ala	Asp	Glu	Phe	Leu	Tyr	Cys	Phe	Leu	Gln	Ser		
		515					520					525					
Ala	Asp	Cys	Pro	Leu	Phe	Lys	Ala	Ala	Ser	Tyr	Pro	Gly	Ser	Gln	Leu		
	530					535					540						
Thr	Asn	Leu	Pro	Pro	Met	Arg	Tyr	Ile	Ser	Val	Leu	Gly	Gly	Ser	Gln		
545					550					555				560			
Glu	Ser	Ser	Gly	Tyr	Thr	Tyr	Arg	Leu	Leu	Gly	Tyr	Leu	Leu	Ser	Gln		
			565					570						575			
Leu	Gln	Pro	Asp	Ile	His	Arg	Asp	Asn	Cys	Thr	Asp	Leu	Pro	Leu	His		
			580					585					590				
Tyr	Phe	Ala	Gly	Phe	Asn	Asn	Ile	Gly	Glu	Cys	Arg	Leu	Thr	Thr	Gln		
	595					600						605					
Asn	Tyr	Ser	His	Ala	Leu	Ser	Pro	Ala	Phe	Leu	Ile	Asp	Gly	Tyr	Asp		
	610					615					620						

19/19

Trp Ser Ser Gly Met Tyr Ser Thr Trp Thr Glu Ser Thr Trp Ser Gln
 625 630 635 640
 Phe Ser Ala Arg Ile Phe Leu Arg Pro Ser Asn Val His Gln Val Thr
 645 650 655
 Thr Leu Ser Val Gly Ile Val Val Leu Ile Ile Ser Phe Cys Leu Val
 660 665 670
 Tyr Ile Ile Ser Ser Arg Ser Glu Val Leu Phe Glu Asp Leu Pro Ala
 675 680 685
 Ser Asn Ala Ala Leu Phe Gly
 690 695

<210> 19

<211> 17

<212> PRT

<213> human

<400> 19

Ala Arg Leu Ala Arg Ala Leu Ser Pro Ala Phe Glu Leu Ser Gln Trp
 1 5 10 15
 Ser

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/00354

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N15/12 C07K14/705 A01K67/027 C12N5/10 C12Q1/68 G01N33/50		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N C07K A01K C12Q G01N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) MEDLINE, BIOSIS, STRAND, EPO-Internal		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NAGASE T ET AL : "Hypothetical protein KIAA0253" SWISSPROT DATABASE ENTRY Y253_HUMAN, ACCESSION NUMBER Q92542, 15 July 1998 (1998-07-15), XP002143447 cited in the application sequence	1,2
X	NAGASE T ET AL: "Human mRNA for KIAA0253 gene" EMBL DATABASE ENTRY HSD442, ACCESSION NUMBER D87442, 9 November 1996 (1996-11-09), XP002143448 cited in the application sequence	7
-/-		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "Z" document member of the same patent family		
Date of the actual completion of the international search 26 July 2000		Date of mailing of the international search report 07/08/2000
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Espen, J

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 00/00354

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JONES SJM: "hypothetical 81.4 kd protein zc434-6" SWISSPROT YHC6_CAEEL, ACCESSION NUMBER Q23316, 15 July 1998 (1998-07-15), XP002143449 cited in the application sequence	1,3
A	YU G ET AL: "The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains beta-catenin." JOURNAL OF BIOLOGICAL CHEMISTRY, (1998 JUN 26) 273 (26) 16470-5. , XP000925470 cited in the application	
A	LEVESQUE G ET AL: "Presenilins interact with armadillo proteins including neural-specific plakophilin-related protein and beta-catenin." JOURNAL OF NEUROCHEMISTRY, (1999 MAR) 72 (3) 999-1008. , XP000925514	